Scientific programme update

Transcription

Valid as of 13th March, 2013
PART I - Coronary interventions
This programme does not include the Abstract (38) and Forum (85) sessions,
nor Hotline and Innovation sessions.
CORONARY INTERVENTIONS
Tuesday 21st May, 2013
Opening sessions
Main arena
__10:00-13:00 ___________________________________________
Opening
Chairperson: W. Wijns
LIVE demonstrations from:
c Andreas Grüntzig Laboratories, University Hospital - Zurich, Switzerland
c Clinique Pasteur - Toulouse, France
c Hôpital Henri Mondor - Créteil, France
__13:00-14:30 ___________________________________________
2013 Great Debate
With an unrestricted educational grant from MEDTRONIC
Chairpersons: M. Haude, M. Thomas
Panellists: I. Al Rashdan, A. Baumbach, R. Byrne, T. Cuisset, C. Lotan,
C.K. Naber
__13:00-14:30 _______ Main arena _________________________
2013 Great Debate
C.K. Naber
Attend this session if you want:
c To take part in an informative, lively and balanced debate about the
two most burning unresolved questions in interventional medicine
today
- Coronary bioresorbable scaffolds: what is their role in today’s
clinical practice?
- Dual antiplatelet therapy. Which drug? For which patient?
For which stent? For how long?
___13:30-15:00 _______ Room 241 _______________Plenary session
__14:30-16:30 ___________________________________________
From late breaking trials to clinical practice
Chairperson: P. Vardas
Interventional strategies for thrombus
management in STEMI
Chairpersons: M. Degertekin, S. Jolly
STRELNIFTE
FO
c To be able to manage thrombus-containing lesions
c To appreciate the potential of local pharmaco- and device-based
therapies
c To be able to use and choose customised stent designs
c Introduction and objectives - S. Jolly
c Thrombus removal with manual or mechanical aspiration catheters
F. Saia
c Thrombus management in large vessels or vein grafts - M. Sabaté
c Additive strategies post-thrombectomy in primary PCI for challenging
thrombi - M. Sabaté
c Discussion and audience interaction
c The role of local drug delivery in dissolution of epicardial and
microvascular thrombus - M. Sezer
c The use of self-expanding stents and mesh-based stents - D. Dudek
c Take-home message - M. Degertekin
Risk scores to aid decision making between CABG and PCI
Role of SYNTAX Score II
Chairpersons: J.L. Pomar, P.W. Serruys
c To learn how the established and emerging risk scores can directly
impact on patient care
c To be able to apply SYNTAX Score II in practice
c Introduction and objectives
c What every cardiologist should know about EuroSCORE
c What every cardiac surgeon should know about SYNTAX Score II
c Applying scores in practice: case-based discussions
- First case demonstration
- Discussion and audience interaction
- Second case demonstration
c What about patients with diabetes?
c Take-home message
Embolic stroke and cardiovascular interventions
Chairpersons: J. Moret, J. Rodes Cabau
c To understand the frequency, timing and predictors of embolic stroke
in patients undergoing cardiovascular interventions
c To be familiar with the acute management of embolic stroke after
cardiovascular interventions
c To know strategies to prevent embolic stroke in patients with atrial
fibrillation and patent foramen ovale
c Introduction and objectives - J. Rodes Cabau
c Timing, predictors and outcome of embolic stroke after cardiovascular
interventions - S. Windecker
c Acute management of patients with embolic stroke during
cardiovascular interventions - M. Roffi
c Role of embolic protection devices to prevent stroke during
cardiovascular interventions - J. Webb
c Type and duration of antithrombotic therapy after device implantation
in patients with atrial fibrillation - M. Valgimigli
c Role of left atrial appendage occlusion in patients with atrial fibrillation
H. Sievert
c Percutaneous patent foramen ovale closure for secondary prevention
of embolic stroke among patients with patent foramen ovale - B. Meier
c Take-home message - J. Moret
___14:00-16:30 ______ Theatre Bleu ______________Plenary session
NIC@EuroPCR - Interventional procedures complicated
with fatal outcome
With the collaboration of the National Intervention Council of India
c To understand what risk factors can be contributive of mortality
in a patient undergoing PCI
c To comprehend how risk evaluation can be incorporated into
procedure planning and performance
c To take home useful tips and checklists for prevention
of complications
14:05-14:45 LIVE demonstration from Andreas Grüntzig Laboratories,
University Hospital - Zurich, Switzerland
c A selection of clinical cases presented by the National Intervention
Council of India
Valid as of 13th March, 2013 / Scientific programme update
3
…Tuesday 21st May, 2013
___14:00-15:30 _____ Theatre Havane _________________________
___14:00-16:30 _______Room 342A __________ How should I treat?
Learning bifurcations
How to successfully perform PCI in a patient presenting
complex bifurcation lesions requiring two stents
Facilitators: M. Lesiak, G. Stankovic
Patients in whom PCI is preferred over CABG
Under the auspices of the Working Group on Interventional Cardiology
of the Croatian Cardiac Society, the Working Group on Interventional
Cardiology of the Cyprus Society of Cardiology, the South African Society
of Cardiovascular Interventions (SASCI) and the Working Group on
Interventional Cardiology of the Serbian Society of Cardiology
Chairpersons: P. Avraamides, A. Ernst, F. Hellig, M. Ostojic
c To better understand which two-stent bifurcation technique to use for
which patient
c To better understand and perform the different two-stent techniques
c To better understand how to use the current available dedicated stent
systems
Stent for Life
2012 ESC STEMI guidelines implementation
Chairpersons: O. Goktekin, P. Kala
Panellist: A. Al Nooryani
STRELNIFTE
FO
c To present new ESC STEMI guidelines focused on a system changes
c To share with the audience what programmes and activities are in
place in Stent for Life countries to address 2012 ESC STEMI guidelines
c To share experience in implementing primary PCI programmes
around the globe
c Introduction and objectives - O. Goktekin
c New ESC STEMI Guidelines – Focus on system and transportation
protocols - S.D. Kristensen
c Stent for Life Portugal: the role of transportation protocols and time
delays measurement - H. Pereira
c Stent for Life Romania: role of emergency physician in STEMI
management - C. Cimpoesu
c Developing the STEMI care in India - T. Alexander
c Developing the STEMI care in China - J. Li
c Reperfusion strategies in South Africa - S. Khan
c Impact of ACT NOW. SAVE A LIFE educational public awareness
campaign on shortening the time delays - Z. Kaifoszova
c Take-home message - P. Kala
c To understand how to select appropriate treatment modality in
patient-centred approach
c To share the complementary role of PCI and CABG in the course of
progression of coronary artery disease
c To be able to safely perform complex procedures in high-risk patients
c Introduction and objectives - A. Ernst
c Case presentation: STEMI, distal left main coronary artery culprit lesion
and cardiogenic shock – Against odds - V. Tomulic
- How would I treat? - G.M. Georgiou
- How would I treat? - K. Stambuk
- How did I treat? - V. Tomulic
- Consensus - A. Ernst
c Case presentation: urgent PCI instead of surgery with subsequent
restenosis - T. Komodromos
- How would I treat? - M. Abelson
- How would I treat? - G.M. Georgiou
- How did I treat? - T. Komodromos
- Consensus - P. Avraamides
c Case presentation: multivessel disease – Who should choose the
therapy? - C. Zambakides
- How would I treat? - S. Stojkovic
- How would I treat? - M. Abelson
- How did I treat? - C. Zambakides
- Consensus - F. Hellig
c Case presentation: which approach is better in the course of disease
progression? - M.A. Nedeljkovic
- How would I treat? - K. Stambuk
- How would I treat? - S. Stojkovic
- How did I treat? - M.A. Nedeljkovic
- Consensus - M. Ostojic
c Take-home message - M. Ostojic
4
___14:00-15:30 _______ Room 343 ___________ How should I treat?
___15:30-16:30 ______ Room 352AB ______________Plenary session
Intracoronary haemodynamic paramaters for evaluation
of coronary lesion severity during cardiac catherisation
How should we use them for clinical decision making
Under the auspices of the British Cardiovascular Intervention Society (BCIS)
and the Working Group on Interventional Cardiology of the Netherlands
Society of Cardiology (WIC)
Chairpersons: A. Banning, R. Van der Schaaf
Clinical impact of stent design – What’s new in 2013?
c To learn the importance of coronary haemodynamic in obstructive
artery disease
c To teach methodology of FFR, coronary flow reserve and
instantaneous wave-free ratio
c To understand and provide insight into the interpretation of
intracoronary haemodynamic parameters for evaluation of coronary
lesion severity
c Introduction and objectives - A. Banning
c Case presentation: FFR is abnormal, but coronary flow reserve is
normal, what to do now? - M. Meuwissen
- How would I treat? - J. Davies
- How would I treat? - J.J. Piek
- How did I treat? - M. Meuwissen
- Consensus - A. Banning
c Case presentation: FFR appears to be normal but instant wave-free
ratio is abnormal. What to do now? - T. Lockie
- How would I treat? - J. Davies
- How did I treat? - T. Lockie
- Consensus - R. Van Der Schaaf
c Take-home message - R. Van Der Schaaf
___14:00-15:30 _______Room 352A __________ Young practitioners
You are facing a patient candidate to PCI:
how to build your strategy and select your material?
Coordinator: G. Ducrocq
Senior advisor: E. Grube
Facilitators: O. Gämperli, A. Wolf
c To get a step-by-step logical process in order to provide your patient
with the best clinical outcome
c To better understand how to appropriately select material
Interested by the other ‘Young practitioners’ sessions?
The next one is tomorrow at 08:00 in the same room...
___14:00-15:30 ___ PCR Sharing Centre _______________________
Understand what you see with the iPad Atlas of OCT
Interactive OCT image interpretation
Facilitators: H.M. Garcia-Garcia, L. Räber, M. Radu, P.W. Serruys
c To fully understand the principles of OCT
c To become familiar with OCT interpretation, especially with regards to
atherosclerosis and evaluation of intracoronary stents
c To be able to identify pitfalls in OCT image interpretation
c Stent conformability – Nice pictures or clinically relevant?
c Systematic surveillance of stent failure – Insights from Japan
c Stent design – Implication for your practice
c Take-home message
___16:45-18:45 ______ Theatre Bleu ______ Tools & Techniques (TNT)
Left main PCI using transradial approach
With an unrestricted educational grant from TERUMO
Chairpersons: J. Fajadet, G. Stankovic
Panellists: H.M. Garcia-Garcia, R. Kornowski, J.F. Lassen, J. Mehilli
c To appreciate decision making process for best treatment option for
one individual patient with complex lesion
c To optimise both strategy and technique utilising novel imaging
technologies and PCI devices
c To demonstrate the value of transradial approach for complex PCI
procedures
c Introduction and objectives - G. Stankovic
16:50-17:35 LIVE demonstration from Clinique Pasteur - Toulouse, France
c Glide Sheath Slender: new Terumo concept to minimise access site
puncture
c Clinical evidence of Nobori DES in left main - J. Mehilli
c Take-home message - J. Fajadet
___16:45-18:15 _____ Theatre Havane _______________ Symposium
Incorporating bioresorbable vascular scaffolds in daily
clinical practice: the time has come
With an unrestricted educational grant from ABBOTT VASCULAR
Chairpersons: A. Colombo, P.W. Serruys
c To review the most recent data supporting the use of bioresorbable
vascular scaffolds in your practice
c To learn from the emerging clinical experiences about the use of
bioresorbable vascular scaffolds
c To learn about the added value of vascular reparative therapy in daily
clinical practice
c Introduction and objectives - A. Colombo
c Vascular reparative therapy – how it works - P.W. Serruys
c Most recent findings from ABSORB clinical trial programme
A. Bartorelli
c The patients I select to be treated with bioresorbable vascular
scaffolds - C.K. Naber
c How to apply bioresorbable vascular scaffolds in clinical practice
A. Colombo
c Take-home message - P.W. Serruys
__14:30-16:30 _______ Main arena __________________Hot Line
5
___16:45-18:15 _______ Room 241 _________________ Symposium
___16:45-18:15 ______ Room 342A __________ How should I treat?
Percutanous haemodynamic support in high-risk PCI
and cardiogenic shock: your safety net in the cathlab
With an unrestricted educational grant from ABIOMED
Chairpersons: W. O’Neill, C. Spaulding
Panellists: D. Burkhoff, J. Henriques, P. Hunziker, J. Lasala
Mechanical device support during PCI: when, to whom
and which device?
With an unrestricted educational grant from
MAQUET Cardiovascular GETINGE GROUP
Chairpersons: N.H. Pijls, S. Redwood
c To understand the science of haemodynamic support
c To learn about the role of cardiovascular support in high-risk PCI and
cardiogenic shock
c To discuss with an experienced panel your benefit from
haemodynamic support devices
c To understand the real-world experience and outcomes in treating
complex PCI procedures
c To share experiences with higher efficacy mechanical devices in
complex challenging cases
c Introduction and objectives - W. O’neill
c The science of haemodynamic support including interactive
simulation - D. Burkhoff
c PROTECT II: 90-day results in high-risk PCI - J. Lasala
c Current clinical data on Impella in cardiogenic shock - J. Henriques
c Experiences with percutaneous haemodynamic support in
cardiogenic shock - P. Hunziker
c Questions and answers with the panel: patients, indications and
devices
c Take-home message - C. Spaulding
STRELNIFTE
FO
c Introduction and objectives - S. Redwood
c Case presentation - N. Kapur
- How would I treat? - D. Perera
- How would I treat? - M. Noc
- How did I treat? - N. Kapur
- Consensus - N.H. Pijls
c Case presentation - M. Abdel-Wahab
- How did I treat? - M. Abdel-Wahab
- Consensus - N.H. Pijls
c Take-home message - S. Redwood
___16:45-18:15 ______ Room 242AB __________ How should I treat?
Coronary chronic total occlusion: set up your strategy to achieve
success while keeping it simple
Chairpersons: E. Barbato, G. Werner
c To learn how to balance the different coronary chronic total occlusion
techniques and the patient’s benefit
c To understand how to achieve acute success and long-term outcomes
with innovative devices
c Introduction and objectives - G. Werner
c Case presentation: antegrade versus retrograde – How to balance
complexity and patient benefit? - N. Boudou
- How would I treat? - J. Spratt
- How would I treat? - T. Schmitz
- How did I treat? - N. Boudou
- Consensus - E. Barbato
c Case presentation: wire crossed the lesion – What now? Choosing
between novel technologies - J. Escaned
- How would I treat? - J. Spratt
- How would I treat? - T. Schmitz
- How did I treat? - J. Escaned
- Consensus - G. Werner
c Take-home message - E. Barbato
6
Wednesday 22nd May, 2013
___08:00-09:30 ______ Room 242AB ___________ Innovation session
__08:00-12:00 _______ Main arena _________________________
Complex cardiovascular interventions and new techniques
Master LIVE demonstrations by Jean Fajadet & Talib Majwal
and expert panel discussion
With continuous LIVE demonstration from Clinique Pasteur - Toulouse,
France and Dubai Heart Center - Dubai, United Arab Emirates
11:15-11:45 Ethica award
Novel stents and scaffolds
Chairpersons: R. Gao, P.W. Serruys
c To become familiar with stents and scaffolds that have been
developed in the Far East
c To learn about potential indications and specific techniques for
deployment of novel stents
c To appreciate the potential of nanotechnologies for novel drug
delivery systems in development
Structured care pathways for NSTE-ACS: best practice examples
Chairpersons: C.K. Naber, F. Ribichini
Challenging coronary artery intervention in ACS
Under the auspices of the Iranian Society of Interventional Cardiology
(ISOIC) and the Russian Society of Interventional Cardioangiology
Chairpersons: M. Hashemian, D.G. Iosseliani
c To understand different approaches to pre-hospital and
periprocedural pharmacological management of NSTE-ACS
c To compare best practices from real life with guidelines
recommendations
c To gather ideas to construct your own recipe
c Introduction and objectives - F. Ribichini
08:05-08:50 LIVE demonstration from Erasmus University Medical Center,
ThoraxCenter - Rotterdam, The Netherlands
c Discussion of the LIVE case
c Pharmacological treatment strategy for NSTE-ACS in:
- Finland - K. Niemela
- Poland - D. Dudek
- Spain - M. Sabaté
- The Netherlands - J.J. Piek
c Take-home message - C.K. Naber
___08:00-09:30 ____ Theatre Bordeaux ____________Plenary session
The best way to diagnose ischaemia in my patient? Convince me!
Personal views from interventional cardiologists
Chairpersons: A. Baumbach, M.C. Morice
c To understand primary PCI of culprit lesion in STEMI
c To learn how to treat complication during primary PCI
c To review and discuss complex PCI cases
c Introduction and objectives - M. Hashemian
c Case presentation: acute occlusion of the left main coronary artery in
STEMI – Immediate and mid-term results - A. Koledinsky
- How would I treat? - M. Ostovan
- How would I treat? - D. Asadov
- How did I treat? - A. Koledinsky
- Consensus - D.G. Iosseliani
c Case presentation: primary PCI of left anterior descending followed by
left main stem angioplasty - M.H. Namazi
- How would I treat? - D. Asadov
- How would I treat? - M. Ostovan
- How did I treat? - M.H. Namazi
- Consensus - M. Hashemian
- Take-home message - D.G. Iosseliani
c To understand what you get from different modalities to diagnose
ischaemia in your patient from an interventionalist perspective
c To learn about the non-invasive practice of a renowned
interventionalist
c Introduction and objectives - A. Baumbach
08:05-08:40 LIVE demonstration from Edinburgh Heart Centre Royal
Infirmary - Edinburgh, United Kingdom
c Exercise electrocardiogram is useless - A. Banning
c Single photon emission computed tomography: oldie but goldie
O. Gämperli
c One-stop-shop magnetic resonance imaging tells me all - M.C. Morice
c Without hesitation: straight to the cathlab - B. De Bruyne
c Take-home message - M.C. Morice
7
…Wednesday 22nd May, 2013
How to treat a patient with complex multivessel disease
and/or left main disease
Under the auspices of the Argentine College of Interventional
Cardioangiologist (CACI) and the Atheroma Coronary and Interventional
Cardiology Group (GACI)
Chairpersons: H. Le Breton, E. Torresani
Tough calls in primary PCI: STEMI and multivessel disease
of the Israeli Heart Society and the Working Group on Interventional
Cardiology of the Slovenian Society of Cardiology
Chairpersons: M. Bunc, H. Danenberg
c To learn how patients with complex multivessel disease and/or left
main disease are managed in different countries
c To understand how to integrate scientific data available for decisionmaking process in daily practice
c To understand how local organisation could explain differences in
practice between countries
c To learn the occurence, pathophysiological complexity and long-term
prognosis of STEMI in patients with multivessel disease
c To understand procedural strategy, prioritisation, risks and benefits,
special technical aspects and adjunctive therapy needed to perform
primary PCI in a patient with multivessel disease
c To share local difficulties and constraints for the treatment of a patient
with complex multivessel disease
c Introduction and objectives - E. Torresani
c Case presentation: how to treat an elderly patient presenting for
high-risk NSTE-ACS with distal left main disease and abdominal aortic
aneurysm? - D. Chambre
- How would I treat? - E. Teiger
- How would I treat? - F.A. Cura
- How did I treat? - D. Chambre
- Consensus - E. Torresani
c Case presentation: how to treat an elderly diabetic patient presenting
for high-risk NSTE-ACS with distal left main disease? - T. Cuisset
- How would I treat? - A. Cherro
- How would I treat? - T. Lefèvre
- How did I treat? - T. Cuisset
- Consensus - H. Le Breton
c Take-home message - H. Le Breton
c Introduction and objectives - H. Danenberg
c Case presentation: STEMI in an haemodynamically unstable patient
with multivessel disease which includes chronic total occlusion
D. Zorman
- How would I treat? - Y. Rozenman
- How did I treat? - D. Zorman
- Consensus - H. Danenberg
c Case presentation: STEMI in a patient with multivessel disease and an
ambiguous culprit lesion - A. Assali
- How would I treat? - Y. Rozenman
- How did I treat? - A. Assali
- Consensus - M. Bunc
c Take-home message - M. Bunc
Transradial approach for complex coronary interventions
in patients with ACS
of the Hungarian Society of Cardiology and the Working Group on
Interventional Cardiology of the Macedonian Society of Cardiology
Chairpersons: S. Kedev, I. Ungi
Intravascular diagnostics - Does it really change our treatment
strategy?
Under the auspices of the Working Group on Interventional Cardiology of
the Danish Society of Cardiology and the Working Group on Interventional
Cardiology of the Norwegian Society of Cardiology
Chairpersons: A. Iqbal, A. Junker
c To learn the role of transradial approach to reduce the risk of access
site and bleeding complication in patients with ACS
c To understand how to improve the results of transradial approach
after the learning curve
c To acknowledge how to achieve a successful transradial programme
c To learn about the intravascular diagnostic methods
c To understand how to interprete intravascular diagnostic information
c To understand the way intravascular diagnostic information should
change our treatment strategy
c Introduction and objectives - S. Kedev
c Case presentation: acute left main thrombotic occlusion in patient
presenting with anterior wall STEMI and cardiogenic shock - H. Pejkov
- How would I treat? - G. Fontos
- How would I treat? - J. Kostov
- How did I treat? - H. Pejkov
- Consensus - I. Ungi
c Case presentation: a complex PCI from radial access in a STEMI patient
B. Merkely
- How would I treat? - J. Kostov
- How would I treat? - G. Fontos
- How did I treat? - B. Merkely
- Consensus - S. Kedev
c Take-home message - I. Ungi
c Introduction and objectives - A. Junker
c Case presentation: cause of angiographic silent intermittent ischaemia
determined by OCT - E. Christiansen
- How would I treat? - T. Trovik
- How would I treat? - T. Engstroem
- How did I treat? - E. Christiansen
- Consensus - A. Junker
c Case presentation: a lady with a chainsaw - A. Kristensen
- How would I treat? - T. Engstroem
- How would I treat? - T. Trovik
- How did I treat? - A. Kristensen
- Consensus - A. Iqbal
c Take-home message - A. Iqbal
8
You are facing an elderly patient presenting with high-risk
NSTE-ACS: how to successfully perform PCI?
Facilitators: P. Calvert, R. Didier
Panellist: P. Kahlert
Complex bifurcation stenting: LIVE demonstration of emerging
techniques
Chairpersons: R. Kornowski, M. Lesiak
Panellist: G. Stankovic
c To better understand how to manage your patient with specific
situation (eg: multiple comorbidities, complex multivessel disease,
difficult anatomy...)
c To find out how to overcome or manage the most frequent issues
The next one is this afternoon at 14:10 in the same room...
___08:00-08:45 _______ Room 353 ______________________Forum
Czech Republic shares its most educational cases
the Czech Society of Cardiology
Chairperson: J. Stasek
c Introduction
c Rare complication during PCI – breakaway of balloon catheter
c Aortic annulus rupture during TAVI – look at the angiogram and
echocardiogram properly and do not be desperate!
c Myocardial infarction with intermittent coronary occlusion
c Consensus
___08:45-09:30 _______ Room 353 ______________________Forum
India shares its most educational cases
Under the auspices of the Cardiovascular Society of India
Chairperson: A. Mehta
c Introduction
c Unusual coronary perforation
c Aortic dissection in coronary intervention
c Left main dissection, salvage with 5 stents
c Consensus
c To understand challenges in the management of complex bifurcation
lesions
c To appreciate value of contemporary state-of-the-art imaging and
device technologies in optimisation of complex bifurcation lesion
treatment
c To learn about novel emerging solutions for complex bifurcation
anatomies
c Introduction and objectives - M. Lesiak
c Bifurcation lesions management: the role of conventional and
dedicated therapeutic techniques - G. Stankovic
c Take-home message - R. Kornowski
GRCI@EuroPCR
Challenging cases in the catheterisation laboratory: international
viewpoints
Gestion de cas complexes en salle de cathétérisme: approche
internationale
Bilingual session in collaboration with the GRCI (Groupe de Réflexion sur
la Cardiologie Interventionnelle)
Session bilingue en collaboration avec le GRCI (Groupe de Réflexion sur la
Cardiologie Interventionnelle)
c To reflect on different management strategies that can be applied to
complex cases
c To explore how the approach of French interventionalists might be
different from international colleagues, or not
c To take home some useful tips and tricks for solving challenging
problems
Participez à cette session si vous voulez:
c Réfléchir aux différentes possibilités de traitement de cas complexes
c Evaluer en quoi la pratique interventionnelle en France diffère de celle
adoptée dans d’autres parties du monde
c Apprendre quelques astuces techniques permettant de résoudre des
situations délicates
Chairpersons / Modérateurs: P. Aubry, J.P. Collet
c Welcome and session objectives - J.P. Collet
c Présentation d’un cas clinique
- Audience interaction – International approach
- Comment nous avons traité le patient
- What to remember from the literature
9
c Case presentation
- Interaction avec l’audience – Approche en France
- How we did treat the patient
- Que retenir de la littérature
c Présentation d’un cas clinique
- Audience interaction – International approach
- Comment nous avons traité le patient
- What to remember from the literature
c Résumé et messages à retenir - P. Aubry
___09:45-10:40 _______Room 352A ______________Plenary session
Radial approach - Fundamental rules
Facilitators: H. Benamer, J. Monsegu
c To build on the fundamentals of the transradial approach in order to
start a radial program
Interested by the other sessions ‘Radial approach’?
The next one is at 10:50 in the same room...
How to write a scientific manuscript and get it published!
Chairpersons: P. Cummins, P.W. Serruys
Panellists: A.P. Kappetein, P. Vranckx
c To obtain tips and tricks for a successful publication
c Introduction - P. Cummins
c Writing it up properly! - R. Byrne
c How to read and review a scientific manuscript - L. Räber
c Statistical pitfalls - D. Capodanno
c Impact factors and social media - P. Cummins
c Take-home message - P.W. Serruys
Multivessel disease: “a tale of two cities”
and the Working Group on Interventional Cardiology of the Cyprus Society
of Cardiology
Chairpersons: C. Christou, S. Redwood
c To understand how to approach multivessel disease in the current era
of interventional cardiology
c To learn a stepwise approach to dealing with multivessel disease and
valvular heart disease in high-risk patients
c To appreciate how adjunctive diagnostic and therapeutic tools can
make interventional treatment of complex multivessel disease feasible
and safer
c Introduction and objectives - C. Christou
c Case presentation: FFR and IVUS-guided revascularisation in left main
stem and multivessel disease - S. Constantinides
- How would I treat? - M. Soteriou
- How did I treat? - S. Constantinides
- Consensus - C. Christou
c Case presentation: multivessel percutaneous revascularisation in
severe symptomatic aortic stenosis supported by the Impella left
ventricular assist device - S. Doshi
- How would I treat? - M. Soteriou
- How did I treat? - S. Doshi
- Consensus - S. Redwood
- Take-home message - S. Redwood
___09:45-11:15 _______Room 352B_______________Plenary session
AICT@EuroPCR
With the collaboration of the Asian Interventional Cardiovascular
Therapeutics (AICT)
Chairpersons: J.B. Ge, H.C. Tan, W. Udayachalerm
c To learn about the evolution and current status of PCI for coronary
chronic total occlusion with an array of Asia-developed techniques
and devices
c To learn about the current tips and tricks of both antegrade and
retrograde approaches to PCI for coronary chronic total occlusion
c To learn how to achieve greater success of PCI for coronary chronic
total occlusion
c Introduction and objectives - J.B. Ge
c How do I select my coronary chronic total occlusion guidelines based
on their characteristics? - M. Yamane
c How do I ensure maximal success in my antegrade approach? - S. Nakamura
c Retrograde techniques: step-by-step approach - H.L. Kao
c My best coronary chronic total occlusion - W. Udayachalerm
c My best coronary chronic total occlusion
c My best coronary chronic total occlusion - Y.S. Jang
c Conclusion - H.C. Tan
___09:45-10:30 _______ Room 353 ______________________Forum
Hungary shares its most educational cases
the Hungarian Society of Cardiology
Chairperson: I. Ungi
c Introduction
c Management of left main dissection during diagnostic coronarography
c Serious haemodynamic consequence of occlusive dissection of donor
artery during retrograde coronary chronic total occlusion recanalisation
c When OCT images should have been done
c Consensus
10
___09:45-11:15 ___ PCR Sharing Centre ______________________
Understand what you see with the iPad Atlas of OCT
Interactive OCT image interpretation
Facilitators: H.M. Garcia-Garcia, M. Radu
Do we really need dedicated stents to treat bifurcation lesions?
BIOSENSORS INTERNATIONAL
Chairpersons: B. Garcia Del Blanco, S. Verheye
Panellists: C. Dubois, F. Feres, P. O’Kane, D. Tresukosol, M. Webster
c To fully understand the principles of OCT
c To become familiar with OCT interpretation, especially with regards to
atherosclerosis and evaluation of intracoronary stents
c To be able to identify pitfalls in OCT image interpretation
___10:30-11:15 _______ Room 353 ______________________Forum
Saudi Arabia shares its most educational cases
Under the auspices of the Saudi Arabia Cardiology Interventional Group
(SACIG) of the Saudia Heart Association
Chairperson: M. Balghith
c Introduction
c Right internal carotid pseudoaneurysm after radiation therapy
c Catheter-induced left main dissection
c Myocardial bridging, stent or no stent
c Consensus
Radial approach - Navigation from radial to brachial
Facilitators: S. Hoffmann, J. Monsegu
c To know how to navigate and progress easily and safely, from the
radial to the brachial arteries
c To identify and resolve potential difficulties
c To understand when to stop
The next one is this afternoon at 15:45 in the same room...
___11:15-12:00 _______ Room 353 ______________________Forum
South Africa shares its most educational cases
Under the auspices of the South African Society of Cardiovascular
Intervention (SASCI)
c Introduction
c Spontaneous carotid dissection
c Unusual treatment of coronary perforation
c Neurocardiac complication
c Consensus
c To understand the use and mechanisms of self-expanding dedicated
bifurcation stents – What they can do, why and when we should use
them?
c To master how to use the Axxess dedicated self-expanding bifurcation
stent in complex anatomies
c To learn from OCT imaging about stent strut behaviour at the carina,
at baseline and/or at follow-up
c Introduction and objectives - B. Garcia Del Blanco
c Very long term clinical evidence from the DIVERGE trial: final five year
results - M. Webster
c What you see is what you get: Axxess versus the rest - C. Dubois
c Using Axxess: what can go wrong and how to get out of it? - P. O’kane
c Why do left main bifurcations need a different approach? - F. Feres
c Take-home message - S. Verheye
___12:00-14:00 ____ Theatre Bordeaux ____ Tools & Techniques (TNT)
How the combination of OCT and FFR can lead to better PCI
outcomes in patients with stable and acute coronary artery
disease
With an unrestricted educational grant from ST. JUDE MEDICAL
Chairpersons: T. Akasaka, K.G. Oldroyd
Panellists: G. Guagliumi, J. Mehilli, P. Motreff, S. Uemura
c To learn the complementary role of functional and imaging
techniques to optimise stable and acute patient outcomes
c To experience through a live case FFR and OCT ease of use in the
cathlab
c To discover the role of high resolution imaging in supporting fast
decision making for complex PCI
c Introduction and objectives - T. Akasaka
c How to perform an optimal PCI in today’s cathlab - G. Guagliumi
c Exploring the “state-of-the-art” OCT technology to support fast
decision making - S. Uemura
13:00-13:45 Benefits of OCT in STEMI patients - P. Motreff
c PCI optimisation: can we achieve success with the complementary
role of FFR and OCT? - W. Wijns
c Take-home message - K.G. Oldroyd
11
An in-depth look into the BIOFLOW trials: a modern limus-eluting
stent with bioabsorbable polymer
With an unrestricted educational grant from BIOTRONIK
Chairpersons: R. Byrne, S. Windecker
c To understand the characteristics of the Orsiro hybrid DES and its
potential benefits
c To gain insight into the comparative clinical efficacy of the Orsiro
bioabsorbable polymer stent versus an everolimus-eluting durable
polymer stent
c To assess the value of OCT imaging as intermediate safety endpoint in
patients treated with biodegradable polymer stents
c Introduction and objectives - R. Byrne
c Vascular healing among biodegradable or permanent polymer based
DES: from bench to bedside - M. Joner
c Results from the BIOFLOW-II trial: a randomised comparison of Orsiro
with bioabsorbable polymer versus Xience Prime - S. Windecker
c Insights into IVUS and OCT subgroup analysis of the BIOFLOW-II trial
M. Sabaté
c The Orsiro DES in everyday practice: results and case reports from the
BIOFLOW-III all-comers registry - J. Van Der Heyden
c Panel discussion and audience interaction
c Take-home message - R. Byrne
___12:00-13:00 _______ Room 241 _____________ 60 minutes inside
Chronic total occlusion and multivessel disease
Can novel imaging help to reduce risks?
With an unrestricted educational grant from PHILIPS and INFRAREDX
Chairperson: J. Koolen
Panellists: H. Gehlmann, R.D. Madder, N. Reifart
c To understand the limitations and risks in treating these complex cases
c To learn how to manage procedural and patient complications and
risks in these procedures
c To share how novel imaging innovations can influence treatment
decisions and help to reduce risks
c Introduction and objectives - J. Koolen
c Strategies to treat multivessel diseases and manage contrast and
radiation-induced risks - H. Gehlmann
c Retrograde or antegrade approach – What is needed: techniques,
device and imaging? - N. Reifart
c The relevance of plaque characterisation in multivessel disease and
high-risk patients - R.D. Madder
c Take-home message - J. Koolen
___12:00-13:30 ______ Room 242AB ___ EBAC accredited educational
programme
Real-world considerations for selecting antiplatelet therapy
in high-risk ACS patients: putting evidence into clinical practice
EBAC accreditation will be applied for
Programme supported by an unrestricted educational grant from
ASTRAZENECA
Chairpersons: M. Flather, P.G. Steg
c To appreciate new developments in ACS risk stratification and develop
appropriate treatment strategies to improve outcomes for high-risk
ACS patients
c To understand the issues surrounding short- versus long-term
antiplatelet therapy
c To discuss best practices in antiplatelet therapy from both case-based
and guidelines-based perspectives
c Introduction and objectives - P.G. Steg
c Reducing cardiovascular risk and death: the importance of risk
stratification in ACS - S.R. Mehta
c Optimal duration for oral antiplatelet therapy: treating the stent versus
treating the patient with ACS - M. Valgimigli
c The use of oral antiplatelet agents in ACS: what do the guidelines now
recommend? - M. Flather
c Moderated case: Optimising treatment in high-risk ACS patients
R. Mehran
c Take-home message - P.G. Steg
Management of complex coronary disease in Asia Pacific
Chairpersons: F.Y. Kuo, S. Worthley
c To understand the impact of technology on the treatment of complex
cardiovascular disease in Asia Pacific
c Introduction and objectives - S. Worthley
c Case presentation - B. Zhang
- How would I treat? - Y. Wu
- How would I treat? - S. Nakamura
- How did I treat? - B. Zhang
- Consensus - F.Y. Kuo
c Case presentation - M. Nakamura
- How would I treat? - K.T. Chan
- How would I treat? - J. Shite
- How did I treat? - M. Nakamura
- Consensus - S. Worthley
c Take-home message - F.Y. Kuo
12
___12:00-13:30 _______ Room 351 _________________ Symposium
Synchronising polymer absorption and drug elution with the
Synergy stent. Implications for healing and dual antiplatelet
therapy duration
With an unrestricted educational grant from BOSTON SCIENTIFIC
Chairperson: I. Meredith
Complex patients today and tomorrow: Medtronic DES solutions
from Resolute Integrity to bioresorbable stents
Chairpersons: A. Abizaid, S. Silber
Panellists: F. Burzotta, S. Nathan, S. Salmon
c To learn how polymers and stent materials impact healing
c To understand the current evidence when assessing ischaemic
bleeding and thrombotic risks for specific patient subsets
c To learn how the Synergy stent will be comprehensively studied in
challenging patient subsets
c To discuss real-world complex case examples and challenges: from
unplanned dual antiplatelet therapy discontinuation to complex
bifurcation lesion
c To examine cost effectiveness for complex patients
c To unvail three Medtronic next generation stent programmes
c Introduction and objectives - I. Meredith
c Synchronising a stent to vessel dynamics and healing - J. Escaned
c Dual antiplatelet therapy – A matter of balance in specific subsets
T. Cuisset
c Synergy stent clinical evaluation: trial programme and early practice
K. Dawkins
c Take-home message - I. Meredith
c Introduction and objectives - S. Silber
c The unplanned dual antiplatelet therapy discontinuation
patient – How can I make informed decisions? - S. Silber
c The complex bifurcation patient: new insights into stent selection and
optimal techniques - F. Burzotta
c The complex patient: optimising treatment options and cost
effectiveness - S. Nathan
c Introducing three novel stent technologies to improve future
treatment of these complex patients - S. Salmon
c Take-home message - A. Abizaid
___12:00-13:30 ______ Room 342A __________ Case-based session
Self-expanding stents: a NEW solution for patients presenting
with atypical coronary anatomy
With an unrestricted educational grant from STENTYS
Facilitators: A. Baumbach, R.J. Van Geuns
c To understand the needs for an alternative to balloon expandable
stents
c To better understand why the self-expanding stents respect the
anatomy
c To learn from experienced operators when and how to use
self-expanding stents in your daily practice
c Set the stage: in some situations a tubular stent is not ideal
A. Baumbach
c How does the device work? - J. Wykrzykowska
c Video presentation on how to use the device - R.J. Van Geuns
c Learn from experienced operators:
- Case 1 (bifurcation, left main) - H. Nef
- Case 2 (coronary chronic total occlusion and saphenous vein graft)
S. Ijsselmuiden
- Case 3 (aneurysm, tapered vessel) - G. Amoroso
c Wrap-up - R.J. Van Geuns
___12:00-13:30 _______Room 352B_________________ Symposium
Titanium-nitride-oxide bioactive stent: the evidence-based choice
in STEMI and NSTEMI patients
With an unrestricted educational grant from HEXACATH
Chairpersons: P. Karjalainen, R. Waksman
c To understand the short- and long- term benefits offered with
titanium-nitride-oxide bioactive stents in the setting of STEMI and
NSTEMI patients
c To appreciate the strong advantages of titanium-nitride-oxide
bioactive stents offering a reduced dual-antiplatelet therapy duration
c To evaluate the clinical results of different active stent technologies
such as limus and titanium-nitride-oxide coated stents
c Introduction and objectives - P. Karjalainen
c What is the role of nitride-oxide in the efficacy of Titan stent in patients
with acute coronary syndromes? - O. Varenne
c The latest active stent technologies (bioactive and drug-eluting stents)
and the complex problem of dual-antiplatelet therapy management
in STEMI and NSTEMI patients - W. Nammas
c The new ESC 2012 STEMI guidelines: bioactive stents should be
preferred over DES - M. Angioi
c BASE-ACS randomised study comparing the titanium-nitride-oxide
bioactive Titan2 stent with the Everolimus-eluting stent Xience V:
a 3-year follow-up - P. Karjalainen
c Large scale TITAN2 spanish registry in STEMI and NSTEMI patients
J.A. Gomez-Hospital
c The TIDES-OCT sub-study: a randomised comparison of early
vascular healing with the new Optimax bioactive stent and the
Promus-element stents in STEMI and NSTEMI patients (2 months OCT)
follow-up
c Take-home message - R. Waksman
13
Cardioprotective strategies to reduce ischaemic injury during PCI
With an unrestricted educational grant from MENARINI
Chairperson: G. Montalescot
Complex cardiovascular intervention in patients primarily
reported as ACS
the Czech Society of Cardiology and the Working Group on Interventional
Cardiology of the Slovak Society of Cardiology
Chairpersons: V. Fridrich, J. Stasek
c To learn how important it is to optimise peri-PCI outcomes using new
pharmacological strategies
c To learn about new therapeutic approaches in peri-PCI management
c To understand how ranolazine can be protective for ischaemic injury
c Introduction and objectives - G. Montalescot
c Reducing peri-procedural ischaemic injury: what are the options?
F. Pelliccia
c Mechanisms for ranolazine-induced cardioprotection - R. Zucchi
c Cardioprotection during PCI: what about the future? - A. Cequier
c Take-home message - G. Montalescot
__14:10-16:45 _______ Main arena __________________________
Master LIVE demonstrations by Karl Heinz Kuck & Talib Majwal
With continuous LIVE demonstration from Asklepios Klinik St. Georg Hamburg, Germany and Dubai Heart Center - Dubai, United Arab Emirates
c To understand very complex and unusual cases primarily reported
as ACS
c To comprehend clinical balance in these polymorbid patients with ACS
c To learn how to treat complicate unusual patients by percutaneous
interventions
c Introduction and objectives - V. Fridrich
c Case presentation: ACS patient, discovering and treatment of
underlying diseases - J. Bis
- How would I treat? - M. Zelizko
- How would I treat? - M. Studencan
- How did I treat? - J. Bis
- Consensus - J. Stasek
c Case presentation: aneurysm of proximal left anterior descending
M. Gocar
- How would I treat? - M. Studencan
- How would I treat? - M. Zelizko
- How did I treat? - M. Gocar
- Consensus - V. Fridrich
c Take-home message - J. Stasek
Bioresorbable coronary scaffolds in practice
Chairpersons: M. Haude, P.W. Serruys
Panellists: I. Al Rashdan, M. Sabaté
c To appreciate the evolving indications for bioresorbable scaffolds in
current clinical practice
c To understand the importance of lesion preparation
c To master the technique for adequate scaffold sizing and deployment
c Introduction and objectives - P.W. Serruys
c What should you know about bioresorbable scaffolds before your first
implant - M. Sabaté
14:25-14:55 LIVE demonstration from Dubai Heart Center - Dubai, United
Arab Emirates
c Where and when current bioresorbable scaffolds should not be used
I. Al Rashdan
c Take-home message - M. Haude
PCI in the elderly: when to stop, when to intervene
the Dutch Society of Cardiology and the Working Group on Interventional
Cardiology (GTCI) of the Tunisian Society of Cardiology and Cardiovascular
Surgery
Chairpersons: P. de Jaegere, H. Gamra
c To have a better understanding of the challenges that might be
encountered during PCI in the elderly
c To learn about the tips and tricks for a successful PCI in this patient
group
c To define when to pursue PCI and when to refrain from doing it in the
elderly
c Introduction and objectives - H. Gamra
c Case presentation: successful minimal intervention in a complex case
K. Battikh
- How would I treat? - F. Addad
- How did I treat? - K. Battikh
- Consensus - H. Gamra
c Case presentation: complicated PCI for ACS in the ederly - R. Diletti
- How would I treat? - F. Addad
- How did I treat? - R. Diletti
- Consensus - P. de Jaegere
c Take-home message - P. de Jaegere
14
Complex primary PCI in high-risk STEMI patients
Chairpersons: A. Low, F. Weidinger
You are facing a patient presenting with an acute STEMI
Senior advisor: M.C. Morice
Facilitators: S. Brugaletta, D. Capodanno
Panellist: P. Kahlert
STRELNIFTE
FO
c To understand clinical strategies in high-risk patient subsets
c To select the optimal management of patients with multivessel
disease and cardiogenic shock, including circulatory support devices
c Introduction and objectives - A. Low
c Left main primary PCI - G. Pedrazzini
c PCI during cardiogenic shock - C. Spaulding
c Primary PCI in patients with mechanical complications - P. Kala
14:45-15:15 Recorded LIVE demonstration - Use of circulatory support
(ECMO) - R.J. Van Geuns
c Dicussion of the LIVE case
c Circulatory support after intra-aortic balloon pump shock 2 - H. Thiele
c Take-home message - F. Weidinger
STRELNIFTE
FO
c To better understand how to correctly use manual thrombus
aspiration
The next one is on Thursday at 08:00 in the Peripheral
programme...
___14:10-14:55 _______ Room 353 ______________________Forum
STEMI and multivessel disease
of the Georgian Society of Cardiology and the Working Group on
Interventional Cardiology of the Kazakhstanese Society of Cardiology
Chairpersons: S. Rtskhiladze, O. Sakhov
Switzerland shares its most educational cases
Under the auspices of the Working Goup on Interventional Cardiology and
ACS of the Swiss Society of Cardiology
Chairperson: C. Kaiser
c To understand how to apply the guidelines in clinical practice
c To learn about the possibility of different approaches to the treatment
of the same patient
c Introduction
c A case of acute stroke during TAVI from the transfemoral route with a
self-expanding bioprosthesis
c Severe complications during PCI of an arterial coronary bypass graft
c The nightmare
c Consensus
c Introduction and objectives - O. Sakhov
c Case presentation: STEMI with cardiogenic shock and three vessel
occlusion - D. Teleuov
- How would I treat? - S. Tvalchrelidze
- How would I treat? - M. Aripov
- How did I treat? - D. Teleuov
- Consensus - O. Sakhov
c Case presentation: difficulties in decision making in treatment of ACS
patients with prior CABG - I. Gogorishvili
- How would I treat? - M. Aripov
- How would I treat? - S. Tvalchrelidze
- How did I treat? - I. Gogorishvili
- Consensus - S. Rtskhiladze
c Take-home message - S. Rtskhiladze
___14:10-15:40 _______ Room 351 ____All you need to know about...
All you need to know about OCT
Chairpersons: G. Guagliumi, T. Johnson
___14:55-15:40 _______ Room 353 ______________________Forum
United Kingdom shares its most educational cases
Chairperson: S. Redwood
c Introduction
c A bigger than average air embolus!
c Massive dissection in a short left main – a narrow escape
c Coronary catheter-derived thrombus causing acute left main stem
occlusion
c Consensus
c To obtain a comprehensive update on this field that is relevant to your
clinical practice
c To identify the current evidence base and existing guidelines
c To recognise the open questions that need addressing in the near
future
c Introduction - T. Johnson
c Background: the technology of OCT imaging - G. Guagliumi
c Clinical data: what do the images show? - M. Radu
c Issues in clinical practice: how to perform OCT - E. Regar
c In the absence of guidelines: recommendations for clinical use of OCT
in 2013 - F. Prati
c Unresolved issues and outlook: technical and clinical developments
T. Johnson
c Conclusion - G. Guagliumi
15
___15:40-16:25 _______ Room 353 ______________________Forum
Managing patients with unprotected left main coronary
artery disease
With the collaboration of China Interventional Therapeutics (CIT)
Chairpersons: R. Gao, C. K. Naber
Serbia shares its most educational cases
Under the auspices of the Working Group on Interventional
Cardiology of the Serbian Society of Cardiology
Chairperson: M. Ostojic
c To get practical guidance on how to manage patients with
unprotected left main coronary disease
c To discuss with experts on technical issues in the treatment of
unprotected left main coronary disease
c To learn about differences and similarities regarding the management
of these patients in China and Europe
c A case of complex distal unprotected left main disease
c Distal unprotected left main disease in a diabetic patient
c A case of distal unprotected left main and two vessel disease
c Decision making in left main disease in my clinical practice
c Take-home message
c Introduction
c Unsuccessful primary PCI for the postpartal dissection of all three
major coronary arteries
c Salvage occlusion of ruptured right coronary artery with balloon and
pericardiocentesis for the treatment of cardiac tamponade 24 hours
after primary PCI
c The fatal chain of complications
c Consensus
Radial approach - Navigation from brachial artery to ascending
aorta
Facilitators: S. Hoffmann, J. Monsegu
STRELNIFTE
FO
c To define the challenges of primary PCI care in countries with large
territories and long transfer time
c To find the best solutions for implementing the ESC STEMI guidelines
in large regions
c To evaluate the progress of primary PCI care in Russia
c Introduction and objectives - V. Ganuykov
c How to achieve the Stent for Life targets in large countries?
Z. Kaifoszova
c Complex primary PCI case - A.G. Osiev
c Development of the PCI and primary PCI programme in Russia
B. Alekyan
c Siberian region: primary PCI achievements and barriers - A. Protopopov
c Take-home message - P. Kala
How to write a scientific abstract and get it accepted!
Chairpersons: R. Byrne, A. Kastrati
c Improve your skills in preparing scientific submissions in abstract form
c Discuss good and bad examples of previously submitted abstracts
(anonymously!)
c Improve your understanding of what pleases or irritates reviewers
c Introduction - R. Byrne
c Interactive discussions:
- Choosing the right title
- What pleases and what irritates reviewers?
- Common mistakes that can be easily avoided
- Statistics: common pitfalls
c Take-home message - A. Kastrati
FO
How to improve the STEMI treatment in large
territories like Russia?
Chairpersons: V. Ganuykov, P. Kala
STRELNIFTE
c To know how to navigate and progress easily and safely, from the
brachial artery to the ascending aorta
c To identify and resolve potential difficulties
c To understand when to stop
The next one is tomorrow at 09:45 in the same room...
Interventional management of high-risk ACS
Don’t just do it... do it right!
and THE MEDICINES COMPANY
Chairpersons: T. Cuisset, P. Kala
c To appreciate the diversity and current management of ACS patients
c To learn about the best synergies of the optimal procedural and
pharmacological choices
c Introduction and objectives - P. Kala
c Case presentation - T. Cuisset
c From ESC guidelines to the cathlab – How well we do it in Europe?
c Discussion and audience interaction - A. van’t Hof
c Optimised choices of technology and pharmacolgy - M. Valgimigli
c Interventional treatment of NSTEMI – The clock is also ticking!
A. Kastrati
c Coronary imaging: right focus for the right decision - L. Räber
c Take-home message - T. Cuisset
16
___16:45-18:15 _______ Room 251 _________________ Symposium
___16:45-18:15 ______ Room 342A ________________ Symposium
Clinical value of anti-restenosis and pro-healing Combo stent
With an unrestricted educational grant from ORBUSNEICH
Chairpersons: M. Haude, S. Silber
Ischaemia-driven revascularisation
The evolution of FFR in daily practice
Chairpersons: A. Bartorelli, P. L’Allier
c To explore differences between monotherapy DES and dual therapy
stents with both anti-restenotic and pro-healing attributes
c To understand how we can still improve monotherapy DES
c To learn the benefits of dual therapy stents with case-based
discussions
c Introduction and objectives - M. Haude
c Where are we with monotherapy DES? - R. Virmani
c What are the true unmet needs? With case-based discussions
R. Mehran
c How do we design clinical studies beyond DES to show incremental
benefits of dual therapy stents? - R.J. De Winter
c What is the potential for Combo dual therapy stent to address unmet
needs? With case exemples - M. Haude
c Take-home message - S. Silber
DES and dual antiplatelet therapy
Customising treatment duration to your patient
Chairpersons: S. Kedev, M. Sabaté
c To review the latest data on optimal dual antiplatelet therapy duration
after DES implantation
c To learn how to translate the current evidence and guidelines into
clinical practice
c To understand clinical implication of your choice on dual antiplatelet
therapy duration
c Introduction and objectives - M. Sabaté
c Case presentation: need for surgery in a patient 4 months following
DES implantation – What to do? - J. Strange
- How would I treat? - S. Kedev
- How would I treat? - J. Hill
- How would I treat? Views from the audience - S. Kedev
- How did I treat? - J. Strange
- Consensus - M. Sabaté
c Case presentation: a STEMI patient with high bleeding risk - O. Varenne
- How would I treat? - S. Kedev
- How would I treat? - J. Hill
- How would I treat? Views from the audience - S. Kedev
- How did I treat? - O. Varenne
- Consensus - M. Sabaté
c Take-home message - S. Kedev
c To share the latest clinical evidence on ischaemia-driven
revascularisation
c To learn how to optimise patient outcomes in times of hospital
budget constraints
c To discover the benefits of assessing non culprit lesions in ACS
procedures
c Introduction and objectives - P. L’Allier
c Landmark evidence, ease of use, cost-effectiveness: the importance of
bringing FFR into daily practice - N.H. Pijls
c The role of FFR in diagnostic angiography: how can this influence
patient treatment strategies - N. Curzen
c FFR in ACS decision making: when to use it and what value does it
add - K.G. Oldroyd
c Diagnostic of ischaemia: non invasive versus invasive techniques to
support workflow efficiency. Should we update the guidelines for
coronary artery disease? - P. L’Allier
c Take-home message - A. Bartorelli
___16:45-18:15 _______Room 352B_________________ Symposium
A new combination of factor Xa inhibition and standard
antiplatelet therapy to prevent more recurrent cardiovascular
events in ACS
BAYER HEALTHCARE PHARMACEUTICALS
Chairpersons: C.M. Gibson, G. Montalescot
c To understand the importance of the interplay between the
coagulation cascade and platelets in arterial thrombus formation:
thrombin generation remains high even after platelet hyperactivity
retained to normal
c To comprehend the rationale for oral antiplatelet and anticoagulant
therapy to reduce residual thromboembolic risk for patients following
ACS
c To acknowledge the significant reduction of cardiovascular mortality
and stent thrombosis in patients following ACS when combining
rivaroxaban 2.5mg BID and standard antiplatelet therapy
c Introduction and objectives - C.M. Gibson
c Thrombin generation and its critical role in ACS: combining
anticoagulant and antiplatelet therapy in the acute phase and in
secondary prevention of ACS - P.G. Steg
c New era of anticoagulation: reducing mortality and preventing stent
thrombosis in ACS patients when combining rivaroxaban 2.5mg BID and
standard antiplatelet therapy – The ATLAS 2 TIMI 51 trial - C.M. Gibson
c Translating survival benefit into clinical practice in patients following
ACS: choosing the right patient - R. Welsh
c Rivaroxaban: proven experience and new clinical activities - C. Bode
c Take-home message - G. Montalescot
17
Thursday 23rd May, 2013
__08:00-12:00 _______ Main arena _________________________
Master LIVE demonstrations by Corrado Tamburino, Martyn
Thomas & Simon Redwood and expert panel discussion
With continuous LIVE demonstration from St Thomas’ Hospital - London,
United Kingdom and Ferrarotto Hospital - Catania, Italy
11:30-12:00 Innovation Award
Revascularisation in a patient with ischaemic heart failure
and reduced left ventricular function
Chairpersons: P. Kolh, T. Lüscher
Panellists: J. Bartunek, P. Kala
c To apply appropriate revascularisation strategies in patients with
ischaemic heart failure
c To understand open issues surrounding revascularisation treatment
for heart failure patient and the need for a patient-tailored and heart
team-guided multidisciplinary approach
c To understand the role of catheter-based devices for haemodynamic
support during high-risk PCI
c Introduction and objectives - P. Kolh
c Revascularisation strategies in patients presenting with heart failure:
clinical assessment and contemporary guidelines - J. Bartunek
08:20-09:05 LIVE demonstration from Kerckhoff Clinic - Bad Nauheim,
Germany
c Revascularisation strategies in congestive heart failure patients:
a synthesis of current knowledge and open questions - P. Kala
c Take-home message - T. Lüscher
___08:00-09:30 _____ Theatre Havane ______ Learning pathway (LP)
Optimal management of a NSTE-ACS patient with complex
multivessel disease
Pathway coordinator: T. Cuisset
Facilitators: H. Amin, T. Johnson, M. Noc
c To review and reflect on the key recent data
c To understand how to integrate knowledge and experience in the
decision making for each individual patient
Restenosis after failure of CABG and PCI
Cardiology of the Finnish Society of Cardiology
Chairpersons: J. Aaroe, H. Romppanen
c To understand the risk of restenosis in bare metal and DES in diabetic
patients
c To learn the strategies of revascularisation after occluded arterial and
venous grafts
c To share the treatment strategies of complex genuine vessel and graft
lesions
c Introduction and objectives - J. Aaroe
c Case presentation: restenosis in bare metal and DES - K. Kervinen
- How would I treat? - M. Niemela
- How would I treat? - J.K. Madsen
- How did I treat? - K. Kervinen
- Consensus - J. Aaroe
c Case presentation: the saphenous vein graft to the right coronary
artery fails - E. Christiansen
- How would I treat? - J.K. Madsen
- How would I treat? - M. Niemela
- How did I treat? - E. Christiansen
- Consensus - H. Romppanen
c Take-home message - H. Romppanen
Challenges in acute myocardial infarction
the Austrian Society of Cardiology and the Working Goup on Interventional
Cardiology and ACS of the Swiss Society of Cardiology
Chairpersons: C. Kaiser, H. Schuchlenz
c To learn how to deal with complex lesions in acute myocardial
infarction
c To apprehend how to treat cardiogenic shock in acute myocardial
infarction
c To learn how to manage mechanical complications in acute
myocardial infarction
c Introduction and objectives - C. Kaiser
c Case presentation: percutaneous closure of a post-myocardial
infarction ventricular septal defect – We thought we had done a good
job - G. Pedrazzini
- How would I treat? - G. Christ
- How would I treat? - S. Cook
- How did I treat? - G. Pedrazzini
- Consensus - C. Kaiser
c Case presentation: left main trifurcation occlusion presenting with
STEMI in cardiogenic shock - H. Alber
- How would I treat? - S. Cook
- How would I treat? - G. Christ
- How did I treat? - H. Alber
- Consensus - H. Schuchlenz
c Take-home message - H. Schuchlenz
18
…Thursday 23rd May, 2013
All you need to know about bioresorbable scaffolds
Chairpersons: A. Bartorelli, M. Haude
Treatment of coronary chronic total occlusion:
Japan meets Europe
With the collaboration of Complex Cardiovascular Therapeutics (CCT)
Chairpersons: E. Barbato, M. Yamane
clinical practice
future
c Introduction - A. Bartorelli
c Background: the technology of disappearing stents - M. Haude
c Clinical data: the evidence so far? - A. Abizaid
c Issues in clinical practice: how to implant a scaffold - I. Al Rashdan
c In the absence of guidelines and recommendations: current
application - J. Ormiston
c Unresolved issues and outlook: ongoing trials and future technology
P.W. Serruys
c Conclusion - M. Haude
___08:00-09:30 ______ Room 352B ___All you need to know about...
All you need to know about treatment of coronary
chronic total occlusion
Chairpersons: E. Barbato, G. Werner
clinical practice
future
c Introduction - G. Werner
c Background: clinical relevance of coronary chronic total occlusion
E. Barbato
c Clinical data: trials and registries - A. Mehta
c Issues in clinical practice: the techniques explained - D. Tchetche
c In the absence of guidelines and recommendations: overview of
different approaches - C. Thompson
c Unresolved issues and outlook: ongoing trials and new technology
G. Werner
c Conclusion - E. Barbato
___08:00-08:45 _______ Room 353 ______________________Forum
Tunisia shares its most educational cases
(GTCI) of the Tunisian Society of Cardiology and Cardiovascular Surgery
Chairperson: H. Gamra
___08:45-09:30 _______ Room 353 ______________________Forum
Italy shares its most educational cases
Under the auspices of the Working Group on Invasive Cardiology of the
Italian Society of Invasive Cardiology (SICI-GISE)
Chairperson: A. Cremonesi
c Introduction
c When the ‘better’ is the ‘worst’
c How to avoid (or better not) restenosis of ostial circumflex following
left main stenting
c Challenging atrial septal defect percutaneous closure in patient with
inferior vena cava thrombosis
c Consensus
c To identify the appropriate patient for percutaneous revascularisation
of coronary chronic total occlusion, balancing procedural risks and
expected clinical outcome
c To increase success rates with antegrade PCI of coronary chronic total
occlusion through careful planning of the procedural strategy, and
superior understanding of the available tools and techniques, and of
their optimal use
c To understand the different approaches to PCI of coronary chronic
total occlusion between operators from different regions of the world
With continuous LIVE demonstration from Institut Cardiovasculaire Paris
Sud - Massy, France
c Spot lectures:
- Indication and patient selection
- New guidewires for coronary chronic total occlusion
- Specialty catheters
- When to stop and when to stage a PCI of coronary chronic total
occlusion
c Take-home message
___09:45-11:45 ______ Room 242AB _______ Glimpse into the future
Preclinical studies of upcoming bioresorbable scaffolds
Chairpersons: Y. Onuma, P.W. Serruys
c To understand the potential of bioresorbable scaffolds in the
treatment of coronary artery disease
c To learn the principles of biodegradation and vascular restoration in
response to bioresorbable scaffolds
c To gain insight into preclinical data of bioresorbable scaffolds
c Introduction and objectives – Why metallic DES should be replaced by
bioresorbable scaffold - P.W. Serruys
c Preclinical evaluation of the bioresorbable scaffolds: what to be
assessed and which model to be used - R. Virmani
c What do we want to know from preclinical studies: a clinician’s point
of view (inflammation, bifurcation and strut fracture) - Y. Onuma
c Overview of the field and summary of published animal data
H.M. Garcia-Garcia
c Preclinical evaluation of:
- a novolimus-eluting scaffold - S. Verheye
- a bioresorbable scaffold with a racemic mixture of L- and D-lactides
A. Lafont
- magnesium stent - B. Warnack
- drug-eluting CD34 antibody-coated bioresorbable scaffold made of a
mixed polymer - R. Cottone
- polylactic acid bioresorbable scaffold eluting a new limus drug with a
hybrid scaffold design (Meril life technology) - R.J. Van Geuns
- sirolimus-eluting scaffold (Xinsorb)
c Take-home message - Y. Onuma
19
Antiplatelet and antithrombotic therapy in PCI: a balancing act
Chairpersons: T. Cuisset, M. Valgimigli
Interventional treatment of acute ischaemic stroke
Which role for STEMI networks?
Chairpersons: J. Moret, P. Widimsky
c To learn about the balance between ischaemic versus bleeding risk in
contemporary PCI scenarios
c To identify how to manage patients needing both antiplatelet and
anticoagulant agents
c To analyse how new antithrombotic agents may be applied into
practice
c Introduction and objectives - M. Valgimigli
c Debates – Oral anticoagulant should be:
- stopped before elective PCI - A. Rubboli
- continued throughout PCI - P. Karjalainen
c Presentation of a case included in the WOEST trial - G. Amoroso
c Balancing ischaemic versus bleeding risk in an individual patient
D. Angiolillo
c Presentation of a case included in the ARCTIC trial - G. Cayla
c Take-home message - T. Cuisset
How to write a scientific manuscript and get it published!
Chairpersons: P. Cummins, P. De Feyter
Panellists: A.P. Kappetein, P. Vranckx
c To obtain tips and tricks for a successful publication
c Introduction - P. Cummins
c Writing it up properly! - M. Joner
c How to read and review a scientific manuscript - L. Räber
c Statistical pitfalls - D. Capodanno
c Impact factors and social media - P. Cummins
c Take-home message - P. De Feyter
STRELNIFTE
FO
c To evaluate opportunities for STEMI networks to engage in the
interventional treatments of acute ischaemic stroke
c To learn about similarities and differences between acute ischaemia of
the heart and the brain
c To consider entering this potential new field of interventional
medicine
c Introduction and objectives – My vision
c Diagnostic approach to acute stroke: complex imaging versus fast
track
c Case-based discussion of best practices
- Case presentation
- Case presentation
c Potential of existing STEMI networks to treat acute stroke
- Acute myocardial infarction and acute stroke: similarities and
differences
- Mechanical intervention with or without fibrinolytics?
- Training requirements for interventional cardiologists
- Next steps – Who? How? Where?
c Take-home message
___09:45-11:45 ______ Room 342B ______________Plenary session
Resuscitated cardiac arrest - Burning interventional questions
Chairpersons: P. MacCarthy, M. Noc
c To appreciate the growing importance of this difficult clinical problem
c To understand when to perform immediate coronary angiography
after resuscitated cardiac arrest and how to proceed with PCI
c To master indications and methods of cooling with special emphasis
on methods that can be used in the cathlab
c Introduction and objectives - M. Noc
c Patients with resuscitated cardiac arrest: a growing problem – Should
they enter primary PCI network? - P. Carli
c Indications and benefits of immediate coronary angiography?
A. Baumbach
c Revascularisation strategy – Scientific evidence or expert opinion
only? - U. Zeymer
c Cooling in the cathlab – For whom, when and how? - G. Olivecrona
c Role of extracorporeal circulation and assist devices - O. Varenne
c Take-home message - P. MacCarthy
___09:45-10:40 ______ Room 352A ______________Plenary session
Radial approach - Cannulation of the targeted vessels ostia
Facilitators: J. Monsegu, H. Routledge, N. Salvatella
c To know how to easily and safely succeed with appropriate
cannulation of the targeted vessels ostia
Want to continue the discussion on this subject in a friendly and
relaxed atmosphere? Join the Forum at 10:50.
20
___09:45-10:30 _______ Room 353 ______________________Forum
___10:45-11:45 _______ Room 253 ____________ Innovation session
Egypt shares its most educational cases
Under the auspices of the Working Group on Interventional
Cardiology (EWGIC) of the Egyptian Society of Cardiology
Chairperson: S. El Tobgy
ABC for biotechnology innovators@EuroPCR
Chairpersons: R. Kornowski, C. Lotan
STRELNIFTE
FO
c Introduction
c Surviving an embolic-thrombotic disaster
c Primary PCI: unforgotten event
c Spontaneous healing of a perforated tortuous right coronary artery
c Consensus
___10:00-11:45 ______ Room Maillot ______________Plenary session
Therapeutic embolisation - Part I: tools and techniques
for coronary and peripheral arteries
Chairpersons: C. Rabbia, C. Schonholz
Panellists: A. Belli, J. Lammer, J. Van den Berg
c To learn about different types of embolic agents
c To discuss clinical indications for the use of those embolic agents
c To master step-by-step technique and learn how to avoid and
manage complications
c Introduction and objectives - C. Schonholz
10:05-10:55 LIVE demonstration from Hôpital Européen Georges
Pompidou - Paris, France
c Introduction and classification of embolic agents
- Mechanical embolic agents:
Free delivery and detachable coils - J. Lammer
Vascular occluders - C. Schonholz
- Particulate embolic agents:
Gelfoam – Polyvinyl alcohol particles - J. Van Den Berg
Microspheres and other new embolic agents - J. Van Den Berg
- Liquid embolic agents:
Cyanoacrylate – Onyx - A. Belli
c Take-home message - C. Rabbia
___10:30-11:15 _______ Room 353 ______________________Forum
France shares its most educational cases
Under the auspices of the Atheroma Coronary and Interventional
Cardiology Group (GACI)
Chairperson: T. Lefèvre
c To understand the pathways of biotechnical innovation
c To learn about the importance of the major steps to success
c Introduction and objectives - C. Lotan
c How to determine if a new device is needed - M.B. Leon
c Preclinical assessment of cardiovascular devices - J. Granada
c Building an innovation company and the importance of intellectual
property - P.J. Fitzgerald
c Financing an innovation company - R. Beyar
c Tips and tricks for success in innovation - A. Cribier
___10:50-11:45 ______ Room 352A _____________________Forum
Forum on radial approach
Facilitators: H. Benamer, B. Farah, S. Hoffmann, J. Monsegu,
H. Routledge, N. Salvatella
c To share in a friendly atmosphere the issues you encounter in your
daily practice of radial interventions
c To obtain answers from experts to all your burning questions
c To participate in a case-based discussion on major complications
___11:15-12:00 _______ Room 353 ______________________Forum
Kazakhstan shares its most educational cases
the Association of Cardiologists of Kazakhstan
Chairperson: O. Sakhov
c Introduction - O. Sakhov
c Perforation of a coronary artery - A. Sadykov
c Thrombosis of a coronary artery during PCI - M. Aripov
c Migration of thrombus in coronary arteries - D. Teleuov
c Consensus - O. Sakhov
c Introduction
c Unusual proximal left anterior descending angiographic ambiguity:
helpfull contribution of OCT
c Post angioplasty delayed internal mammary artery graft false
aneurysm
c About a case: multiple complications in real life daily practice
c Consensus
21
___12:00-13:30 _______ Room 241 _________________ Symposium
Left main and complex bifurcation stenting
Chairpersons: E. Barbato, M.C. Morice
Panellists: A. Chieffo, D. Hildick-Smith, Y. Onuma, M. Valdés Chávarri
Innovating vascular restoration: paving the way for the DESolve
scaffold platform
With an unrestricted educational grant from ELIXIR MEDICAL
Chairpersons: A. Abizaid, M.B. Leon
c To understand how to build the decision making process in order to
propose the best treatment option for one individual patient
c To learn how to optimise outcome for the patients presenting with
left main or complex bifurcation lesions by applying contemporary
state-of-the-art technique
c To assess the value of optical frequency domain imaging in
optimisation of left main and complex bifurcations treatment
c To discuss long-term clinical performance of the durable polymer
DESyne novolimus-eluting DES and the biodegradable polymer
DESyne BD novolimus-eluting DES
c To gain insight into the unique performance features and pre-clinical
testing of Elixir’s DESolve novolimus-eluting bioresorbable scaffold
c To discuss long-term clinical follow-up using multiple imaging
modalities from DESolve FIM and to discuss the impact of the primary
endpoint results of the DESolve Nx multicentre pivotal clinical trial
c Introduction and objectives - M.C. Morice
12:05-12:50 LIVE demonstration from Institut Cardiovasculaire Paris Sud Massy, France
c The role of imaging in PCI of lesions in left main and bifurcation
A. Chieffo
c Long-term clinical outcome of Nobori DES in left main and bifurcation
D. Hildick-Smith
c Take-home message - E. Barbato
c Introduction and objectives - A. Abizaid
c DESyne and DESyne BD clinical data - B. Witzenbichler
c DESyne scaffold pre-clinical data - J. Ormiston
c DESolve scaffold first-in-man clinical data - S. Verheye
c DESolve Nx trial first report data - A. Abizaid
c Take-home message - M.B. Leon
___12:00-13:30 _____ Theatre Havane ______________ Symposium
Contemporary ACS antithrombotic therapy
THE MEDICINES COMPANY
Chairpersons: M. Gibson, P.G. Steg
c To discuss the upgraded role of effective thrombin and P2Y12
inhibition in ACS management
c To discuss contemporary therapeutic options and latest trial evidence
supporting the guidelines
c To discuss the need for teamwork and leadership to further improve
outcomes
c Introduction and objectives - P.G. Steg
c Understanding the crucial targets for antithrombotic therapy in ACS
P.G. Steg
c State of the art therapeutic options in the acute setting - A. Baumbach
c Effective anticoagulation for high-risk PCI: where getting it right really
counts - M. Gibson
c The foundation for successfully running an interventional cardiology
system - L. De Luca
c Take-home message - M. Gibson
___12:00-13:30 ______ Room 242AB ________________ Symposium
The Embolic Protection Stent - Beyond current techniques
A more effective solution in STEMI primary PCI
With an unrestricted educational grant from INSPIRE MD
Chairperson: J. Fajadet
Panellist: C. Lotan
c To understand the challenges and needs in STEMI and primary PCI
treatment
c To explore clinical trials design and clinical end points in acute
myocardial infarction and STEMI patients
c To review the benefits provided by an effective primary PCI procedure
with the Embolic Protection Stent
c The unmet needs and challenges in STEMI primary PCI
c Demonstrative clinical case - R. Kornowski
c MASTER trial update - S. Silber
c What is the MGuard role in primary PCI today? - A. Colombo
c Take-home message - J. Fajadet
22
___12:00-13:30 _______Room 342A __________ Case-based session
___12:00-13:30 ______ Room 352B ________________ Symposium
Self-expanding stents: a NEW solution to optimise
primary PCI beyond the open artery
With an unrestricted educational grant from STENTYS
Facilitators: S. Mishra, H. Nef
Provisional treatment approach of a distal left main and true
bifurcation lesion: combination of a dedicated stent in the main
branch and drug-eluting balloon in the side branch
With an unrestricted educational grant from MINVASYS
Chairpersons: B. Garcia Del Blanco, R. Mehran
Panellists: J. Berland, I. Petrov
STRELNIFTE
FO
c To understand why just opening the vessel in acute myocardial
infarction is not enough
c To better understand why the self-expanding stents could be a new
alternative for primary PCI
c To learn from experienced operators when and how to use selfexpanding stents in your daily practice
c Set the stage: just opening the vessel in acute myocardial infarction is
not enough - H. Thiele
c Self-expanding stent for primary PCI: why could this other device be a
new alternative? - E. Christiansen
c Video presentation on how to use the device - J. Diaz Fernandez
c Learn from experienced operators:
c Case 1 (large thrombus, long tapered vessel) - D. Capodanno
c Case 2 (bifurcation in acute myocardial infarction) - H. Nef
c Reflection on multiple cases - P. Motreff
c Wrap-up - H. Nef
Treating complex lesions and patients with bioresorbable
vascular scaffolds
Chairpersons: R.J. Van Geuns, S. Windecker
c To understand the clinical applicability of bioresorbable vascular
scaffolds
c To share experience on bioresorbable vascular scaffolds implantation
in more complex lesions
c To learn which lesion subsets could benefit the most from this
innovative therapy
c Introduction and objectives - R.J. Van Geuns
c Case presentation: treating complex lesions with bioresorbable
vascular scaffolds - T. Münzel
- How would I treat? - D. Dudek
- How would I treat? - I. Al Rashdan
- How did I treat? - T. Münzel
- Consensus - R.J. Van Geuns
c Case presentation: treating an ACS patient - S. Windecker
- How would I treat? - D. Dudek
- How would I treat? - I. Al Rashdan
- How did I treat? - S. Windecker
- Consensus - R.J. Van Geuns
c Take-home message - S. Windecker
c To understand the concept of a combined stent-balloon approach for
bifurcation treatment
c To master the technical aspects of the combined DES / drug-eluting
balloon approach
c To be updated on procedural results of ongoing combined approach
studies
c Introduction and objectives - B. Garcia Del Blanco
c Combined approach step-by-step - R. Mehran
c Provisional approach with the Nile Croco bare metal stent and the
Danubio eluting balloon in both the main branch and side branch
G.A. Sgueglia
c Provisional approach with the Nile PAX DES and Danubio eluting
balloon in a Medina 1.1.1 bifurcation lesion - A. Latib
c Provisional approach with the Nile PAX DES and Danubio eluting
balloon in a distal left main lesion - B. Garcia Del Blanco
c Take-home message - R. Mehran
Emerging clinical use of drug-eluting balloon in challenging
atherosclerotic lesions
Chairperson: G. Richardt
c To understand the specific characteristics of the Lux technology and
its potential benefits
c To assess clinical results of the Lux technology in coronary or
peripheral lesions
c Introduction and objectives - G. Richardt
c How I translate the Pantera Lux results into my daily practice - R. Tölg
c BIOLUX-I case examples: using drug-eluting balloon to optimise
bifurcation treatments - P. Antonio
c Management of femoro-popliteal indications: illustrative examples
from the BIOLUX P-I trial - A. Schmidt
c Take-home message - G. Richardt
__14:10-16:45 _______ Main arena _________________________
Master LIVE demonstrations by Christian Hamm & Corrado
Tamburino and expert panel discussion
With continuous LIVE demonstration from Kerckhoff Clinic - Bad Nauheim,
Germany and Ferrarotto Hospital - Catania, Italy
23
Am I treating the right lesion? Angiography versus
ischaemia-based coronary revascularisation in stable coronary
artery disease patients
Chairpersons: B. De Bruyne, G. Guagliumi
Panellists: D. Holmes, G. Toth
Up-to-date primary PCI technique
Chairpersons: F. Alfonso Manterola, M. Degertekin
c To discuss when angiography alone or in combination with
intracoronary functional assessment should be considered to decide
on coronary revascularisation
c To learn how to incorporate functional assessment in your clinical
practice
c To analyse how future adoption of functional stenosis assessment
might challenge the conclusions of pivotal trials
c Introduction and objectives - B. De Bruyne
14:15-14:55 LIVE demonstration from St Thomas’ Hospital - London, United
Kingdom
c Is ischaemia-driven revascularisation the new gold standard?
D. Holmes
Kingdom
c Results of ISIS registry - G. Toth
c Take-home message - G. Guagliumi
___14:10-15:40 _____ Theatre Havane _________________________
Learning ostial PCI
How to successfully perform PCI in a patient presenting
ostial left main and ostial right coronary artery
Facilitators: F. Burzotta, M. Haude, T. Schmitz
c To acknowledge specific challenge for the treatment of ostial lesions
c To learn tips and tricks for optimal stent positioning and deployment
in ostial lesion
Innovations in Cardiovascular Interventions@EuroPCR 2013
Chairpersons: R. Beyar, C. Lotan
c To understand the importance of biotechnical innovations
c To evaluate outstanding examples of medical innovations presented
at ICI 2012
c The ICI technology parade and presentation of the winner in 2012
R. Beyar
c Sky Medical: innovation start-up of the year - B. Ross
c KYMA - M. Jonas
c Life Watch - H. Ackerman
c Surmodics - G. Hammel
c Tiara - S. Banai
c Corindus - T. Wenderow
c RealView - A. Kaufman
c Take-home message - R. Beyar
STRELNIFTE
FO
c To share experience about the optimal procedural technique for
primary PCI
c To understand new strategic approaches to primary PCI
c To remain up-to-date on the newest developments in primary PCI for
STEMI
c Introduction and objectives - F. Alfonso Manterola
c Transradial versus transfemoral approach - M. Valgimigli
c Manual aspiration versus mechanical thrombectomy versus local drug
delivery - S. Jolly
14:35-15:05 Recorded LIVE demonstration: use of novel approaches during
primary PCI - P. Kala
c Stenting - Bare-metal stent versus DES - S. Brugaletta
c Novel approaches: self expanding, mesh-covered stent, no stent
R.J. Van Geuns
c Take-home message - M. Degertekin
New challenges for high-risk primary PCI in 2013
Under the auspices of the Association of Cardiovascular Interventions (ACVI)
of the Polish Cardiac Society and the Working Group of Acute Cardiology of
the Slovenian Society of Cardiology
Chairpersons: D. Dudek, M. Noc
c To learn about the different options for optimal reperfusion in acute
myocardial infarction with large thrombus burden
c To understand options for haemodynamic support in acute
myocardial infarction complicated by cardiogenic shock
c To reflect on the role of new devices for thrombotic lesions and the
importance of haemodynamic support in view of intra-aortic balloon
pump SHOCK trial results
c Introduction and objectives - D. Dudek
c Case presentation: primary PCI for STEMI complicated by cardiogenic
shock – What to do if intra-aortic balloon pump does not seem to be
enough? - A. Araszkiewicz
- How would I treat? - I. Kranjec
- How would I treat? - J. Legutko
- How did I treat? - A. Araszkiewicz
- Consensus - D. Dudek
c Case presentation: primary PCI in STEMI – What to do if standard
thrombectomy and regular stent does not seem to be enough?
B. Mrevlje
- How would I treat? - J. Legutko
- How would I treat? - I. Kranjec
- How did I treat? - B. Mrevlje
- Consensus - M. Noc
- Take-home message - M. Noc
24
___14:10-15:40 _______Room 352B_______________Plenary session
EuroIntervention / European Heart Journal@EuroPCR
Chairpersons: N. Bruining, U. Landmesser, T. Lüscher, P.W. Serruys
Physiological stenosis assessment with FFR and instant wave-free
ratio: we need both!
With an unrestricted educational grant from VOLCANO
Chairpersons: J. Escaned, P. L’Allier
Panellists: J. Davies, M.J. Kern, J.J. Piek, E. Van Belle, H. Yokoi
c To discover the most recent published data across specialities from all
journals, presented by key experts from the two Editorial Boards
c Introduction - P.W. Serruys
c Influence, novelties and relevance:
- in intervention - P. De Feyter
- in structural heart disease - N. Van Mieghem
- in ACS - M. Sabaté
- in resistant hypertension - F. Mahfoud
___14:10-14:55 _______ Room 353 ______________________Forum
Spain shares its most educational cases
the Spanish Society of Cardiology
Chairperson: R. Trillo Nouche
c Introduction
c Treatment of stent thrombosis
c Complicated course of a spontaneous coronary dissection
c Multiple complications after TAVI
c Consensus
Therapeutic embolisation - Part II: clinical applications
Chairpersons: Z. Krajcer, J. Lammer
Panellists: F. Bourlon, B. Katzen, H. Rousseau
c Introduction and objectives - J. Lammer
15:45-16:03 LIVE demonstration from Hôpital Européen Georges Pompidou
- Paris, France
c Clinical applications:
- Inferior mesenteric artery and lumbar arteries embolisation prior to
aortic abdominal aneurysm repair - J. Lammer
- Embolisation for endoleaks - H. Rousseau
- Visceral artery aneurysms - B. Katzen
- Embolisation for coronary artery fistulas - F. Bourlon
c Take-home message - Z. Krajcer
c To learn how to make intracoronary physiology a simple and practical
complement to angiography
c To stay updated on the latest solutions to facilitate physiological
assessment of coronary stenosis
c To share with your colleagues the application of these technologies in
Live cases and examples from clinical practice
c Introduction and objectives - J. Escaned
c Simple case presentation
Kingdom
- Discussion of the LIVE case
c A hybrid approach using FFR and instant wave free ratio to simplify
stenosis assessment in the cathlab - E. Van Belle
c How does instant wave free ratio compare against other invasive and
non-invasive functional tests? - J.J. Piek
c Multivessel disease case presentation
17:45-18:25 Live demonstration from St Thomas’ Hospital - London, United
Kingdom
- Discussion of the LIVE case
c How new technological solutions and future clinical direction will
address unmet needs in physiological assessment - J. Davies
c Take-home message - P. L’Allier
___16:45-18:15 _____ Theatre Havane ______________ Symposium
Contemporary coronary chronic total occlusion PCI
Integrating the hybrid approach to your practice
Chairpersons: T. DeMartini, S. Walsh
c To learn about coronary chronic total occlusion crossing using
intraluminal re-entry technique and the Bridgepoint devices
c To demonstrate how tailoring coronary chronic total occlusion
crossing strategies to anatomical and morphologic characteristics can
increase coronary chronic total occlusion success
c To understand stenting options in coronary chronic total occlusion PCI
and mechanical considerations for stent choice
c Introduction and objectives - T. Demartini
c Clinical utility of coronary chronic total occlusion PCI:
a patient-oriented perspective - M. Carlino
c Antegrade crossing, intraluminal and re-entry techniques - S. Rinfret
c Hybrid approach to coronary chronic total occlusion: an algorithm for
success - J. Spratt
c Stent challenges in coronary chronic total occlusion PCI - C. Hanratty
c Take-home message - S. Walsh
25
___16:45-18:15 ______ Room Maillot __________ How should I treat?
___16:45-18:15 _______ Room 251 _________________ Symposium
Titanium-nitride-oxide active stent in ACS patients
with or without bleeding risks
Chairpersons: M. Gricar, M. Silvestri
Cre8: welcome back confidence in short dual antiplatelet
therapy with effective DES
With an unrestricted educational grant from CID
Chairpersons: R. Mehran, O. Pachinger
c To understand the benefits of the titanium-nitride-oxide technology
in ACS patients with or without bleeeding risks
c To discuss the dual antiplatelet therapy strategy after stenting in ACS
patients with or without bleeding risks
c To review the dual antiplatelet therapy duration following PCI with
bare metal stents and DES in everyday clinical practice
c To understand the Demonstr8 clinical trial results
c To understand the added safety value of the polymer-free DES
technology
c Introduction and objectives - M. Silvestri
c Case presentation: ACS patient - I. Balevski
- How would I treat? - R. Blanco
- How would I treat? - M. Silvestri
- How did I treat? - I. Balevski
- Consensus - M. Silvestri
c Case presentation: ACS patient with forecasted surgery - V. Ambrosini
- How would I treat? - R. Blanco
- How would I treat? - M. Gricar
- How did I treat? - V. Ambrosini
- Consensus - M. Silvestri
c Take-home message - M. Gricar
___16:45-18:15 _______ Room 241 _________________ Symposium
Tryton growing clinical experience and data displacing provisional
stenting?
With an unrestricted educational grant from TRYTON MEDICAL
Chairpersons: M.B. Leon, P.W. Serruys
c To appreciate the growing clinical evidence behind this dedicated
system that is displacing provisional stenting
c To comprehend real-world usage and features of this dedicated
bifurcation system
c To recognise the growing body of clinical data in left main
c Introduction and objectives - P.W. Serruys
c Coronary bifurcation section
- The Tryton Pivotal IDE study - A. Bartorelli
- Real-world case: transforming the complex to straight forward
J. Wykrzykowska
- Tryton technique optimisation: the role of final kissing and proximal
optimisation technique - J.F. Lassen
c Left main section
- The continuous growing body of clinical data in left main
R.J. Van Geuns
- ULMCA case: tips and tricks - Y. Almagor
c Introduction and objectives - O. Pachinger
c Dual antiplatelet therapy duration in everyday clinical practice
M. Valgimigli
c Demonstr8 trial results - P. Stella
c Cre8 case study - R. Romaguera
c Cre8 clinical evaluations and future perspectives - M. Vrolix
c Take-home message - R. Mehran
What do YOU think? A case-based discussion on biodegradable
versus durable polymer DES in complex patients
BIOSENSORS INTERNATIONAL
Chairpersons: C.K. Naber, A. Serra
c To participate in case-based discussions on treating complex patients
and to exchange experiences and opinions
c To identify simple solutions for treating complex patients and evaluate
the clinical implications of dual antiplatelet therapy duration
c To be updated on the design of future technologies and trials
c Introduction and objectives - A. Serra
c Diabetic patients in the post FREEDOM era: can we still do PCI?
M. Roffi
c What happens to DES in STEMI patients: insights from the
COMFORTABLE AMI OCT sub-study - S. Windecker
c Can you utilise active stents to treat the patients with high bleeding
risk? Which stent, which dual antiplatelet therapy regimen?
T. Engstroem
c What is the long term outlook of our coronary chronic total occlusion
patients after PCI? Is vessel opening enough? - C. Di Mario
c Take-home message - C.K. Naber
26
___16:45-17:30 _______ Room 353 ______________________Forum
Patient with STEMI: learn the best from East and West
Chairpersons: B. Chevalier, A.G. Osiev
Portugal shares its most educational cases
Under the auspices of the Portuguese Association for Interventional
Cardiology (APIC)
Chairperson: H. Pereira
STRELNIFTE
FO
c To assess current knowledge and therapeutic strategies for complex
patients presenting with STEMI
c To learn how to treat STEMI patients outside of guidelines
c To appreciate the regional variations in the best practice in
management of patients with STEMI
c Introduction and objectives - A.G. Osiev
c Case presentation: STEMI patient 400km far from nearest primary PCI
centre – How to proceed? - S. Semitko
- How would I treat? - H. Amin
- How would I treat? - M. Abdel-Wahab
- How did I treat? - S. Semitko
- Consensus - B. Chevalier
c Case presentation: how to treat patient with STEMI on oral
anticoagulation therapy? - G. Sardella
- How would I treat? - H. Amin
- How would I treat? - M. Abdel-Wahab
- How did I treat? - G. Sardella
- Consensus - A.G. Osiev
c Take-home message - B. Chevalier
c Introduction
c How to deal with coronary perforation
c Alcohol septal ablation: is not the door-to-balloon is the
balloon-to-alcohol time. A remote myocardial infarction complication
c A rare cause of cardiac tamponade
c Consensus
___17:30-19:00 _______ Room 343 ______________Plenary session
EAPCI general assembly
c EAPCI Membership
c EAPCI Fellowship programme
c Stent for Life initiative c Registries – TAVI, CICD, ACS
c EAPCI@ESC Congress 2013
c EuroPCR
c PCR London Valves
c Resistant Hypertension Course
c Relations with international societies (CIT, CSI, SOLACI)
c ESC eLearning platform (ESCeL)
c EuroIntervention
c New Initiatives for young interventionalists
27
Friday 24th May, 2013
__09:00-12:30 _______ Main arena _________________________
Master LIVE demonstrations by Martyn Thomas, Simon Redwood
& Farrel Hellig and expert panel discussion
With continuous LIVE demonstration from St Thomas’ Hospital London, United Kingdom & Sunninghill and Sunward Park Hospitals Johannesburg, South Africa
Slow flow and no flow in PCI, not only in ACS:
how to prevent and how to treat it?
Cardiology of the Swedish Society of Cardiology
Chairpersons: L. Hellsten, L. Kjoller-Hansen
Clinical case and abstract awards
___09:00-10:30 _____ Theatre Havane _______ Learning pathway (LP)
Optimal management of a patient with coronary chronic
total occlusion
Pathway coordinator: K. Niemela
Facilitators: H. Moellmann, P. Musialek
c To review and reflect on the key recent data and patient selection
criteria
c To better understand the most appropriate material selection
according to the technical strategy
Bioresorbable versus durable polymer coatings for DES
Chairpersons: A. Kastrati, S. Windecker
c To be aware of the basic chemistry and preclinical results with
bioresorbable polymer coatings used with available DES
c To be familiar with clinical data of current bioresorbable polymerbased DES
c To learn about strategies to assess differences between platforms in
the future
c Introduction and objectives - S. Windecker
c Basics of bioresorbable polymer coatings - A. Lafont
c Preclinical results with bioresorbable polymer coatings - R. Virmani
c Update on clinical trials with bioresorbable polymer-based DES
c Biolimus A9-eluting stents (BioMatrix) - P.W. Serruys
c Biolimus A9-eluting stents (Terumo) - G.B. Danzi
c ISAR-TEST experience with bioresorbable polymer DES - R. Byrne
c Sirolimus released from a bioresorbable polymer – Orsiro
F.J. Neumann
c Everolimus released from a bioresorbable polymer – Synergy
I. Meredith
c Novolimus and myolimus released from a bioresorbable
polymer – the ELIXIR stent - S. Verheye
c Sirolimus released from a bioresorbable polymer with endothelial cell
capturing capability – REMEDEE - M. Haude
c Sirolimus released from a bioresorbable polymer – DESSOLVE (Micell)
c Discussion and audience interaction – Bioresorbable versus durable
polymer coatings for DES: which polymer will prevail in the future and
how can we prove differences in clinical performance? - A. Kastrati
c Take-home message - A. Kastrati
c To be updated on the different theories about slow flow and no flow
c To learn how to prevent and eventually treat slow flow and no flow
c To understand the basic mechanisms in slow flow and no flow and
treatment of the complication
c Introduction and objectives - L. Kjoller-Hansen
c Case presentation: no flow in stable ischaemic heart disease with
severe complication - T. Engstroem
- How would I treat? - T. Kellerth
- How would I treat? - H.H. Tilsted
- How did I treat? - T. Engstroem
- Consensus - L. Kjoller-Hansen
c Case presentation: can rapidly induced hypothermia in STEMI reduce
slow or no flow? - R. Linder
- How would I treat? - H.H. Tilsted
- How would I treat? - T. Kellerth
- How did I treat? - R. Linder
- Consensus - L. Hellsten
c Take-home message - L. Hellsten
___09:00-10:30 ______ Room 342A __________ How should I treat?
Cardiogenic shock and intra-aortic balloon pump
Under the auspices of the Luxembourg Society of Cardiology and the
Working Group on Interventional Cardiology of the Norwegian Society of
Cardiology
Chairpersons: L. Aaberge, J. Beissel
c To learn treatment of STEMI with cardiogenic shock
c To teach different ventricular assistance devices
c To understand evolution of STEMI with cardiogenic shock
c Introduction and objectives - J. Beissel
c Case presentation: STEMI with cardiogenic shock – Should we
abandon the intra-aortic balloon pump? - D. Wagner
- How would I treat? - B. Pereira
- How would I treat? - E.J.S. Packer
- How did I treat? - D. Wagner
- Consensus - J. Beissel
c Case presentation: left main occlusion with cardiogenic shock – Limits
of intra-aortic balloon pump - O.G. Solberg
- How would I treat? - E.J.S. Packer
- How would I treat? - B. Pereira
- How did I treat? - O.G. Solberg
- Consensus - L. Aaberge
c Take-home message - L. Aaberge
28
… Friday 24th May, 2013
___09:45-10:30 _______ Room 353 ______________________Forum
Primary PCI for STEMI
(BWGIC) of the Belgium Society of Cardiology and the Working Group on
Interventional Cardiology of the Scottish Cardiac Society
Chairpersons: W. Desmet, H. Eteiba
Macedonia shares its most educational cases
the Macedonian Society of Cardiology
Chairperson: S. Kedev
c To understand that time is muscle
c To realise the importance of a sound anticoagulant therapeutic
scheme
c To reflect on the best treatment
c Introduction and objectives - W. Desmet
c Case presentation: acute myocardial infarction in three-vessel disease
C. Hanet
- How would I treat? - M. Mcentegart
- How would I treat? - P. Vermeersch
- How did I treat? - C. Hanet
- Consensus - W. Desmet
c Case presentation: management of STEMI – Primary PCI,
pharmacotherapy, haemodynamic support and beyond - M. Lindsay
- How would I treat? - P. Vermeersch
- How would I treat? - M. Mcentegart
- How did I treat? - M. Lindsay
- Consensus - H. Eteiba
c Take-home message - H. Eteiba
___09:00-10:30 ______ Room 352A __________________________
Learning rotablator
How to easily and successfully use rotational atherectomy
Facilitators: I. Al Rashdan, E. Barbato, D. Tchetche
c To review the basic principles, patient and lesion selection for
rotational atherectomy
c To understand how to safely and successfully use a rotational
atherectomy
___09:00-10:30 ______ Room 352B ___All you need to know about...
All you need to know about antiplatelet and
antithrombotic pharmacology for PCI:
NSTEMI and STEMI
Chairpersons: A. Baumbach, M. Valgimigli
STRELNIFTE
FO
clinical practice
future
c Introduction - M. Valgimigli
c Background: antiplatelet and antithrombotic drugs in clinical practice
A. Baumbach
c Clinical data: an update on landmark trial results - D. Angiolillo
c Issues in clinical practice: tailoring treatment to individual patients
T. Cuisset
c Guidelines and recommendations on NSTEMI and STEMI - F. Weidinger
c Unresolved issues and outlook: finding the best drug combination
M. Valgimigli
c Conclusion - A. Baumbach
c Introduction
c Parallel balloon technique for pooling out the ripped balloon from
coronary artery through the radial access
c Stent graft as first choice for treatment of major coronary artery
rupture
c Percutaneous retrieval of embedded large foreign body from right
ventricle through the femoral vein
c Consensus
All you need to know about drug-coated balloons
in coronary and peripheral vascular disease
Chairpersons: B. Scheller, P. Meier
clinical practice
future
c Introduction - B. Scheller
c Background: local drug delivery - P. Meier
c Clinical data: results in coronary and peripheral arteries - B. Cortese
c Issues in clinical practice - B. Scheller
c Guidelines and recommendations: current clinical applications
C.K. Naber
J. Granada
c Conclusion - P. Meier
All you need to know about radial approach for PCI
Chairpersons: O. Bertrand, D. Fraser
clinical practice
future
c Introduction - D. Fraser
c Background: vascular access options and complications - O. Bertrand
c Clinical data: trial results with transradial PCI - S. Jolly
c Issues in clinical practice - D. Fraser
c Guidelines and recommendations - J. Fajadet
c Unresolved issues and outlook - F. Kiemeneij
c Conclusion - O. Bertrand
29
… Friday 24th May, 2013
___10:45-11:30 _______ Room 353 ______________________Forum
Cyprus shares its most educational cases
of the Cyprus Society of Cardiology
Chairperson: T. Komodromos
Closing
Main arena
__12:30-13:30 ___________________________________________
Closing
c Introduction
c Catheter-induced iatrogenic intramural haematoma of the left main
stem resulting in cardiac arrest
c Interesting stent retrieval technique
c Rare complication of an intraaortic balloon pump after very late stent
thrombosis
c Consensus
___11:30-12:15 _______ Room 353 ______________________Forum
Austria shares its most educational cases
of the Austrian Society of Cardiology
Chairperson: H. Schuchlenz
c Introduction
c 68y old man with NSTEMI 4 weeks after CABG, successful intervention
at a high prize
c Coronary angiography in a 72y old women with dyspnoea, radial
access with complications
c Successful mechanical thrombectomy of PCI realted thrombembolic
stroke
c Consensus
30
TRAINING VILLAGE
Room Cordis
Room Cordis
___13:00-15:00 ____________________________________________
___13:00-15:00 ____________________________________________
Radial approach for coronary diagnostic and interventions
hands-on with the experts
CORDIS CARDIAC & VASCULAR INSTITUTE
Trainers: N. Mulvihill, H. Rittger, C. Spaulding
Trainers: D. Fraser, N. Mulvihill, H. Rittger
c To review and discuss challenging cases and understand strategy
options on radial
c To discuss the principle of how to puncture the radial artery and the
steps to prepare
c To learn about the latest evidence on radial approach for coronary
interventions
options on radial
steps to prepare
interventions
Room Cordis
Room Cordis
___09:00-11:00 ____________________________________________
Trainers: N. Mulvihill, H. Rittger, C. Spaulding
options on radial
steps to prepare
interventions
___15:30-16:30 ____________________________________________
Advanced Exoseal: achieving haemostasis and managing
access site complications
Trainer: L. Lonn
c To understand how to reduce the risk of bleeding complications
following vessel closure
c To get a detailed look into the factors that impact haemostasis
c To know how to manage access site complications
___15:30-16:30 ____________________________________________
Advanced tips and tricks: vessel preparation and post dilation
Trainer: J.F. Lassen
c To better understand the value of good lesion preparation in the
treatment of complex lesions
c To underline the importance of post-stent dilatation and lesion
preparation for procedure outcome
Not to be missed...
The Training programme
with an unrestricted educational grant from ST. JUDE MEDICAL
c PCI optimisation – Focus on QUANTIEN and OPTIS
Information on day / time slot will be available soon
31
PART II - Interventions for structural heart disease
INTERVENTIONS FOR STRUCTURAL HEART DISEASE
Opening sessions
Main arena
__10:00-13:00 ___________________________________________
Opening
__13:00-14:30 ___________________________________________
2013 Great Debate
C.K. Naber
__14:30-16:30 ___________________________________________
All you need to know about interventions
for mitral regurgitation
Chairpersons: O. Franzen, C. Ruiz
clinical practice
c To recognise the open questions that need addressing in the near future
c Introduction - C. Ruiz
c Background: pathophysiology, imaging and classification of mitral
regurgitation
c Clinical data: results with surgical and percutaneous repair - F. Maisano
c Issues in clinical practice: how to perform MitraClip - O. Franzen
c Guidelines and recommendations: indications for established
procedures - A. Vahanian
c Unresolved issues and outlook: MitraClip and other device-based
techniques - C. Ruiz
c Conclusion - O. Franzen
___14:00-15:30 _______Room 352B___________ How should I treat?
TAVI nightmares
and the Working Group on Interventional Cardiology (AGIK) of the German
Society of Cardiology (DGK)
Chairpersons: S. Redwood, H. Thiele
c To diagnose unexpected complications during TAVI
c To learn the different treatment options of unexpected TAVI
complications
c To share treatment strategies for deployment complications with both
available valve systems
c Introduction and objectives - S. Redwood
c Case presentation: dislodged balloon expandable valve after
placement - J. Schofer
- How would I treat? - D. Blackman
- How would I treat? - P. Kahlert
- How did I treat? - J. Schofer
- Consensus - S. Redwood
c Case presentation: dislodged self-expanding valve - G. Manoharan
- How would I treat? - P. Kahlert
- How would I treat? - D. Blackman
- How did I treat? - G. Manoharan
- Consensus - H. Thiele
c Take-home message - H. Thiele
Expanding the indication for TAVI: who, why and when?
Chairpersons: P. MacCarthy, O. Wendler
Panellist: N. Van Mieghem
c To critically evaluate the data to support the use of TAVI in
intermediate risk patients
c To appreciate the outcomes after TAVI and surgical aortic valve
replacement in intermediate risk patients
c To identify new and more challenging patient groups who may now
benefit from TAVI
c Introduction and objectives – What do we mean by “intermediate
risk”? - P. MacCarthy
c Case-based debate: TAVI in the intermediate risk patient – A “Heart
Team” discussion
c Where is the evidence? A summary of the current evidence for TAVI in
intermediate risk patients - N. Van Mieghem
c Are we moving too quickly? The question-marks that remain
O. Wendler
c Discussion and audience interaction – Address the limitations of TAVI
and the good outcomes of surgical aortic valve replacement
c Should TAVI continue to expand into challenging patient groups?
E. Garcia
c Take-home message - O. Wendler
33
RSICA@EuroPCR - Combined structural heart disease interventions
With the collaboration of the Russian Scientific Society of Interventional
Cardioangiology
Chairpersons: L. Kokov, D. Meerkin
Emerging technologies for transcatheter aortic
valve therapies - Part I
Chairpersons: E. Grube, T. Walther
c To discuss the impact of treating congenital/structural heart disease in
the presence of coronary heart disease
c To discuss the feasibility and effectiveness of intervening
simultaneously on structural cardiac lesions and coronary disease or
cardiac arrhythmias
c Introduction - L. Kokov
c Simultaneous procedures in combined coronary and structural heart
disease: clinical experience - A. Rudzitis
c Combined structural intervention: congenital heart diseases and
cardiac arrhythmias - I. Khamnagadaev
c Coronary cameral fistulae and associated coronary artery disease
E. Bruckheimer
c Simultaneous procedures: coronary stenting and correction of
structural heart disease - A. Likharev
c Take-home message - D. Meerkin
Percutaneous treatment options for degenerative mitral
regurgitation
Chairpersons: R. Kornowski, F. Maisano
c To review the pathophysiology of primary degenerative mitral
regurgitation
c To appreciate the imaging needed for diagnosis and planning of
mitral regurgitation repair
c To discuss the potential role of MitraClip as an alternative for surgery in
treating mitral regurgitation
c Introduction and objectives - R. Kornowski
c How to assess mitral regurgitation severity and/or need for repair
J. Balzer
c Surgical correction of degenerative mitral regurgitation: the gold
standard - F. Maisano
c The mitral clip for degenerative mitral regurgitation: is it an alternative
for surgery? - O. Franzen
c Case presentation - H. Ince
c How to assess results and outcome - A. Vahanian
c Discussion and audience interaction – How to select the optimal
treatment for degenerative mitral regurgitation?
c Take-home message - F. Maisano
c To understand the potential of adjunctive tools, devices and
techniques to enable transcatheter aortic valve procedures
c Introduction and objectives - T. Walther
c Novel aortic valve imaging tools - L. Büllesfeld
c Novel technologies for access site management - M.B. Leon
c Innovation in aortic balloon valvuloplasty - A. Linke
c Novel embolic protection devices - E. Grube
c Take-home message - E. Grube
Tips and tricks on the four key steps of left atrial appendage
closure: selection, planning, imaging, and guidance
With an unrestricted educational grant from PHILIPS
and ST JUDE MEDICAL
Chairpersons: C. Ruiz, H. Sievert
Panellists: J. Balzer, H. Omran
c To appreciate the anatomical variability in left atrial appendage
closure morphology and the enhancements of next generation left
atrial appendage closure occlusion device in clinical practice
c To understand the role of imaging in planning left atrial appendage
closure procedures for device size selection, placement and
confirmation of device position
c To learn about the role and advantages of X-ray and echo fusion in live
guidance for device placement
c Introduction and objectives - H. Sievert
c Has patient selection changed after ESC atrial fibrillation guidelines
and European Heart Rythm Association (EHRA)-consensus statement?
H. Omran
c The importance of imaging before, during, and after the procedure
J. Balzer
c How EchoNavigator and Amplatzer Amulet help improve procedure
workflow and success - H. Sievert
c Take-home message - C. Ruiz
34
___16:45-18:15 _______ Room 251 _________________ Symposium
___16:45-18:15 _______ Room 351 _________________ Symposium
Treatment of functional mitral regurgitation via percutaneous
annuloplasty
With an unrestricted educational grant from CARDIAC DIMENSIONS
Chairpersons: C. Butter, M. Haude
Transapical TAVI and other surgical transcatheter techniques
EDWARDS LIFESCIENCES, JENAVALVE, MEDTRONIC and SYMETIS S.A.
Chairpersons: V. Falk, L. Van Garsse
c To learn about the patient selection and application of percutaneous
annuloplasty using the Carillon Mitral Contour System
c To understand the implications of the latest multicentre clinical
data that has been generated surrounding percutaneous mitral
annuloplapsty using the Carillon Mitral Contour System
c To view case examples that illuminate the primary procedural
elements required to perform percutaneous mitral annuloplasty using
the Carillon Mitral Contour System
c To learn about new or refined surgical approaches to TAVI
c To learn about why retrograde TAVI is not always a first treatment
choice
c To learn about the new transapical devices and the most up-to-date
data
c Introduction and objectives - C. Butter
c Addressing the anatomic challenges of coronary sinus-based
percutaneous mitral annuloplasty via device design - D. Reuter
c Case-based review of Carillon Mitral Contour System procedural
elements - J. Lipiecki
c Role of echocardiographic assessment in identifying patients for
treatment with the Carillon Mitral Contour System and assessing
post-procedural efficacy - A. Hagendorff
c Assessment of the latest multicentre clinical data featuring the Carillon
Mitral Contour System - A. Latib
c Take-home message - M. Haude
c Introduction and objectives - V. Falk
c Transapical TAVI is alive and well: new and next generation transapical
valves - H. Treede
c Closure devices and other TAVI accessory products - J. Kempfert
c Soft tissue access: less pain, less invasive surgical techniques
D. Holzhey
c Patient treatment strategies: the role of the Heart Team and when to
choose antegrade versus retrograde TAVI - S. Baldus
c New options in surgical TAVI access: the direct aortic experience
V. Bapat
c Recent transapical clinical experience and what is driving improved
outcomes? - T. Walther
c Take-home message - L. Van Garsse
Not to be missed...
The Training programme on TAVI and left atrial appendage
Information on time slots will be available soon
35
__08:00-12:00 _______ Main arena _________________________
___08:00-09:30 _____ Theatre Havane _________________________
Learning TAVI
Access options for TAVI
Facilitators: V. Bapat, M. Gilard, P. MacCarthy
Panellists: J.J. Bax, T. Modine
c To learn about the optimal percutaneous and surgical access options
for TAVI in your patient
Patent foramen ovale closure in patients with cryptogenic
stroke- timed out or role respected?
and the Working Group on Interventional Cardiology of the Danish Society
of Cardiology
Chairpersons: D. Hildick-Smith, L. Sondergaard
c To learn the influence of the RESPECT and PC trials on decision-making
c To share the mechanisms by which appropriate decisions can be made
c To understand the uncertainty surrounding decisions regarding
patent foramen ovale closure
c Introduction and objectives - D. Hildick-Smith
c Case presentation: transient ischaemic attack in patient with no risk
factors for stroke other than patent foramen ovale - T. Keeble
- How would I treat? - O. Franzen
- How would I treat? - M. Mullen
- How did I treat? - T. Keeble
- Consensus - D. Hildick-Smith
c Case presentation: recreational diver with one previous episode of “the
bends” - M. Settergren
- How would I treat? - M. Mullen
- How would I treat? - O. Franzen
- How did I treat? - M. Settergren
- Consensus - L. Sondergaard
c Take-home message - L. Sondergaard
All you need to know about TAVI
Chairpersons: A.P. Kappetein, N. Piazza
clinical practice
future
c Introduction - N. Piazza
c Background - A.P. Kappetein
c Clinical data - M. Thomas
c Issues in clinical practice - R. Kornowski
c Guidelines and recommendations - A. Vahanian
c Unresolved issues and outlook - N. Piazza
c Conclusion - A.P. Kappetein
TAVI: typical and atypical complications
of Polish Cardiac Society and the Saudi Arabia Cardiology Interventional
Group (SACIG) of the Saudia Heart Association
Chairpersons: M. Balghith, Z. Chmielak
c To understand possible typical and atypical complications during TAVI
c To learn how to recognise such complications during TAVI
c To learn how to solve problems with atypical TAVI complications
c Introduction and objectives - M. Balghith
c Case presentation: probable pulmonary artery embolisation during
CoreValve implantation - W. Wojakowski
- How would I treat? - A. Ochala
- How would I treat? - K.F. Al-Shaibi
- How did I treat? - W. Wojakowski
- Consensus - M. Balghith
c Case presentation: leg ischaemia post-TAVI – What to do - A. Almasood
- How would I treat? - K.F. Al-Shaibi
- How would I treat? - A. Ochala
- How did I treat? - A. Almasood
- Consensus - Z. Chmielak
c Take-home message - Z. Chmielak
36
___10:15-11:45 _____ Theatre Havane _________________________
Can left atrial appendage or patent foramen ovale closure prevent
embolic stroke?
Chairpersons: D. Holmes, B. Meier
Panellist: J. Woehrle
Learning mitral balloon valvuloplasty
Mitral balloon valvuloplasty made easy
Facilitators: S. Khan, C.K. Naber, A. Vahanian
Panellist: K.H. Srinivasa
c To review current techniques for the prevention of cardiogenic stroke
c To become familiar with the indications and performance of these
interventional techniques
c To critically appraise the latest randomised trial data
c To review the basic principles and patient selection for mitral balloon
valvuloplasty
c To better understand how to efficiently perform mitral balloon
valvuloplasty
c Introduction and objectives - B. Meier
09:50-10:30 LIVE demonstration from Asklepios Klinik St. Georg - Hamburg,
Germany
10:40-11:20 LIVE demonstration from Maria Cecilia Hospital - Cotignola, Italy
c Patent foramen ovale closure: current status in view of outcomes in
randomised clinical trials - J. Woehrle
c Take-home message - D. Holmes
Emerging technologies for transcatheter aortic
valve therapies - Part II
Chairpersons: M. Thomas, S. Windecker
c To understand the advancement and role of novel transcatheter aortic
valve systems
c Edwards Lifesciences – Centera - U. Schäfer
c Edwards Lifesciences – Giovani - J. Webb
c Medtronic – Evolut and InVia R - E. Grube
c JenaValve transfemoral technology - S. Baldus
c Portico transapical technology - F. Maisano
c Symetis transfemoral technology - A. Abizaid
c ValveXchange – Vanguard - I. Vesely
c New valve technology transfemoral heart valve system - P. Wenaweser
c Colibri heart valve - B. Chevalier
c Heart leaflet technology - G. Schuler
c Valve medical technologies - M.B. Leon
c Thubrikar valve - M.B. Leon
c Future of transcatheter valve implantation for degenerative
bioprosthetic surgical valves – Optimal device selection - N. Piazza
c Take-home message - M. Thomas
The Direct Flow valve: innovation for improving outcomes in TAVI
With an unrestricted educational grant from DIRECT FLOW MEDICAL
Chairperson: T. Lefèvre
c To learn about the Direct Flow TAVI technology, clinical case
management, and DISCOVER clinical trial results
c Introduction and objectives - T. Lefèvre
c Transcatheter aortic valve system: technology and techniques
F. De Marco
c Clinical case review of Direct Flow Medical technology - A. Colombo
c DISCOVER trial clinical results - J. Schofer
c Take-home message - T. Lefèvre
__14:10-16:45 _______ Main arena __________________________
What to do with coronary artery disease in TAVI candidates?
Chairpersons: R. Kornowski, T. Modine
Panellists: D. Hildick-Smith, S. Windecker
c To review the scope of the clinical problem of TAVI candidates with
obstructive coronary disease
c To explore the indication and criteria for coronary revascularisation
in the setting of TAVI
c Introduction and objectives - T. Modine
c Combined TAVI and coronary artery disease: defining the scope of the
clinical problem - S. Windecker
c Treating coronary artery disease in TAVI patients: why, how and when?
D. Hildick-Smith
37
___14:10-15:40 _____ Theatre Havane _________________________
Learning closure procedures
Patent foramen ovale and left atrial appendage
closure made easy
Facilitators: F. Bourlon, B. Meier
Planning is the key to avoiding TAVI complications
of the Polish Cardiac Society and the South African Society of Cardiovascular
Chairpersons: D. Dudek, F. Hellig
c To learn how to select appropriate patients for the above procedures
c To learn about simple techniques for successful and safe completion
of the procedures
How to avoid patient-prosthesis mismatch and aortic
regurgitation after aortic valve interventions
Chairpersons: A.S. Petronio, M. Thomas
c To define the haemodynamic profile of transcatheter and surgical
aortic valves
c To discuss procedural planning and techniques to optimise
haemodynamic outcome
c To define the accurate assessment of residual aortic regurgitation over
time
c Introduction and objectives - A.S. Petronio
c How to ensure properly sized aortic valve area in TAVI and surgical
aortic valve replacement patients - L. Büllesfeld
c Patient-prosthesis mismatch in patient subsets: women, valve-in-valve,
low flow, low gradient aortic stenosis - H. Baumgartner
c Modalities to reliability assess aortic regurgitation after TAVI
M. Monaghan
c How to manage significant residual aortic regurgitation - J.C. Laborde
c New generation valves designed to reduce aortic regurgitation
G. Manoharan
c Take-home message - M. Thomas
c To learn how to manage a complication of TAVI
c To learn how to prevent complication during TAVI procedure
c To understand the importance of planning a TAVI implant procedure
c Introduction and objectives - F. Hellig
c Case presentation: embolised TAVI balloon expanded valve - H. Weich
- How would I treat? - A. Witkowski
- How would I treat? - T. Mabin
- How did I treat? - H. Weich
- Consensus - F. Hellig
c Case presentation: cerebral protection during TAVI - P. Kleczynski
- How would I treat? - T. Mabin
- How would I treat? - A. Witkowski
- How did I treat? - P. Kleczynski
- Consensus - D. Dudek
c Take-home message - D. Dudek
TAVI and coronary artery disease: what is the best
treatment strategy?
the Latvian Society of Cardiology and the Russian Society of Interventional
Cardioangiology
Chairpersons: A. Erglis, D.G. Iosseliani
c To understand the significance of the combination of aortic valve
disease and coronary artery disease
c To learn whether it is appropriate to perform TAVI simultaneously with
coronary revascularisation
c To understand the advantages and the drawbacks of simultaneous
versus staged procedures
c Introduction and objectives - D.G. Iosseliani
c Case presentation: TAVI and coronary revascularisation in an ederly
patient - O. Sukhorukov
- How would I treat? - A. Erglis
- How would I treat? - S. Semitko
- How did I treat? - O. Sukhorukov
- Consensus - D.G. Iosseliani
c Case presentation: TAVI in a high SYNTAX score patient - I. Narbute
- How would I treat? - S. Semitko
- How would I treat? - A. Erglis
- How did I treat? - I. Narbute
- Consensus - A. Erglis
c Take-home message - A. Erglis
38
___14:10-14:55 _______ Room 353 ______________________Forum
___16:45-18:15 _______ Room 351 _________________ Symposium
Switzerland shares its most educational cases
Under the auspices of the Working Goup on Interventional Cardiology and
ACS of the Swiss Society of Cardiology
Chairperson: C. Kaiser
The Medtronic transcatheter valve programme
Recapturability and multiple transcatheter solutions
Chairpersons: A. Linke, S. Windecker
Panellists: E. Grube, R. Lange, N. Piazza, P. Wenaweser
c Introduction
c A case of acute stroke during TAVI from the transfemoral route with a
self-expanding bioprosthesis
c Severe complications during PCI of an arterial coronary bypass graft
c The nightmare
c Consensus
Acurate positioning of transapical and transfemoral aortic valves
with self-seating and self-sealing design
With an unrestricted educational grant from SYMETIS S.A.
Chairpersons: E. Van Belle, T. Walther
Panellists: A. Abizaid, C. Huber
c To understand the indications and techniques of TAVI
c To successfully deploy Symetis’ Acurate TAVI valves, both
transfemorally and transapically
c To appreciate the available clinical data of the Symetis Acurate
portfolio
c Introduction and objectives - E. Van Belle
c Why I like transapical - T. Walther
17:00-17:35 LIVE demonstration from University Heart Centre - Hamburg,
Germany
c Clinical benefits of Acurate transapical - T. Walther
c Why I like transfemoral - A. Abizaid
Germany
c Clinical benefits of Acurate transfemoral - A. Abizaid
c The best of both: percutaneous transapical? - C. Huber
c Take-home message - T. Walther
c To discover the 1-year results of a large real-world cohort:
the ADVANCE study
c To be exposed to Medtronic’s recapturable technology and first
transapical solution
c To appraise Medtronic’s innovation pipeline and solution offering
beyond TAVI
c Introduction and objectives - A. Linke
c The TAVI real-world study results: the ADVANCE study 1-year update
and composite endpoint results (MACE) - P. Wenaweser
c The recapturable platform: recorded LIVE procedure – CoreValve
Evolut R with InVia R delivery system - E. Grube
c The Medtronic transapical solution: the Engager - R. Lange
c Looking beyond TAVI: Medtronic transcatheter mitral valve
programme - N. Piazza
c Take-home message - S. Windecker
___17:30-18:15 _______ Room 353 ______________________Forum
Germany shares its most educational cases
(AGIK) of the German Society of Cardiology (DGK)
c Introduction
c Dislocation and successful implantation of different prosthesis
c Unexpected severe complication during TAVI
c A complicated rotablation
c Consensus
Not to be missed...
39
__08:00-12:00 _______ Main arena _________________________
Enabling technologies for TAVI
Chairpersons: U. Gerckens, P. Stella
c To appreciate the range of adjunctive technologies currently available
to improve TAVI outcomes
c To review the emerging use of cerebral protection devices
c To review the clinical relevance of new imaging techniques
c Introduction – The remaining challenges of TAVI: optimum access
route, imaging and cerebrovascular events - U. Gerckens
c Discussion and audience interaction:
- TAVI without stroke – A realistic dream? Stroke prevention strategies:
devices and pharmacology
- Vascular closure after TAVI – How far are we from the perfect device?
- Imaging techniques to optimise TAVI results – What really gives added
value?
c Take-home message - P. Stella
Challenges in complex percutaneous valve treatment
The combination of aortic stenosis and significant functional
mitral regurgitation
Chairpersons: M.B. Leon, S. Windecker
c To study the complex pathologies of aortic stenosis combined with
functional mitral regurgitation
c To describe the imaging methods needed to assess and quantify
functional mitral regurgitation in the presence of aortic stenosis
c To review treatment options for aortic stenosis together with
functional mitral regurgitation
c Pathology of functional mitral regurgitation in patients with severe
aortic stenosis - H. Baumgartner
c Imaging and quantification of functional mitral regurgitation in
patients with severe aortic stenosis - J.J. Bax
c Surgical options and results in treatment of patients with severe aortic
stenosis together with functional mitral regurgitation - F. Maisano
c MitraClip for treatment of persistent functional mitral regurgitation
after TAVI, a case-based discussion - K.H. Kuck
c Percutaneous interventional options and results in treatment of
patients with severe aortic stenosis together with functional mitral
regurgitation - J. Rodes Cabau
Prevention and management of complications after TAVI
Under the auspices of the Portuguese Association for Interventional
Cardiology (APIC) and the Working Group on Interventional Cardiology of
the Spanish Society of Cardiology
Chairpersons: P. Braga, R. Trillo Nouche
c To learn how to prevent certain relatively frequent and serious
complications after TAVI
c To learn how to detect them as early as possible
c To learn how to manage them
c Introduction and objectives - R. Trillo Nouche
c Case presentation: significant aortic regurgitation following TAVI
B. Garcia Del Blanco
- How would I treat? - D. Cacela
- How would I treat? - R. Hernandez Antolin
- How did I treat? - B. Garcia Del Blanco
- Consensus - R. Trillo Nouche
c Case presentation: left main occlusion during TAVI - R. Teles
- How would I treat? - R. Hernandez Antolin
- How would I treat? - D. Cacela
- How did I treat? - R. Teles
- Consensus - P. Braga
c Take-home message - P. Braga
How to treat a patient with significant paravalvular leak after TAVI
and the Atheroma Coronary and Interventional Cardiology Group (GACI)
Chairpersons: D. Hildick-Smith, H. Le Breton
c To understand what is a significant paravalvular leak after TAVI
and how it may impact the outcome
c To learn the different mecanisms of paravalvular leak and how
to prevent them
c To learn how to treat different types of paravalvular leaks
c Introduction and objectives - H. Le Breton
c Case presentation: how to treat a significant paravalvular leak after
Edwards valve implantation? - S. Chassaing
- How would I treat? - G. Manoharan
- How would I treat? - N. Dumonteil
- How did I treat? - S. Chassaing
- Consensus - H. Le Breton
c Case presentation: how to treat a significant paravalvular leak after
CoreValve implantation? - D. Blackman
- How would I treat? - N. Dumonteil
- How did I treat? - D. Blackman
c Take-home message - D. Hildick-Smith
40
___08:45-09:30 _______ Room 353 ______________________Forum
Italy shares its most educational cases
Under the auspices of the Working Group on Invasive Cardiology
of the Italian Society of Invasive Cardiology (SICI-GISE)
ABC for biotechnology innovators@EuroPCR
Chairpersons: R. Kornowski, C. Lotan
c Introduction
c When the ‘better’ is the ‘worst’
c How to avoid (or better not) restenosis of ostial circumflex following
left main stenting
c Challenging atrial septal defect percutaneous closure in patient with
inferior vena cava thrombosis
c Consensus
Percutaneous treatment options for functional mitral
regurgitation
Chairpersons: M. Haude, A. Vahanian
Panellists: J.J. Bax, D. Pfeiffer, J. Schofer
c To study the different pathologies of functional mitral regurgitation
c To describe different percutaneous treatment options for functional
mitral regurgitation
c To discuss guided imaging modalities for therapeutic mitral
regurgitation interventions
c Introduction and objectives - M. Haude
c Imaging technologies to diagnose and quantify functional mitral
regurgitation - J.J. Bax
10:00-11:00 LIVE demonstration from Ferrarotto Hospital - Catania, Italy
c Case-based presentation of Carillon implantation in functional mitral
regurgitation - D. Pfeiffer
c Future interventional treatment options of functional mitral
regurgitation - J. Schofer
c Take-home message - A. Vahanian
c To understand the pathways of biotechnical innovation
c To learn about the importance of the major steps to success
c How to determine if a new device is needed - M.B. Leon
c Preclinical assessment of cardiovascular devices - J. Granada
c Building an innovation company and the importance of intellectual
property - P.J. Fitzgerald
c Financing an innovation company - R. Beyar
c Tips and tricks for success in innovation - A. Cribier
Optimising TAVI procedures and patients outcomes
CoreValve recapturable platform and valve-in-valve procedure
Chairpersons: S.J.D. Brecker, D. Tchetche
Panellists: U. Gerckens, T. Modine, N. Van Mieghem, A. Assali
c To understand the occurrence, mechanism of action and impact of
the post-implant aortic regurgitation
c To appreciate Medtronic’s recapturable technology solution and to
discover a technology solution to reduce vascular complications
c To appraise a new TAVI indication, the valve-in-valve implantation and
be exposed to the related procedural tips and tricks
c Introduction and objectives - S.J.D. Brecker
c Aortic regurgitation and paravalvular leak post-implant: diagnostic
assessment and therapeutic options - N. Van Mieghem
c Can we improve vascular complication? The truth about inner / outer
diameters - U. Gerckens
Germany
c TAVI in failing bioprosthesis: surgical valves review and procedural tips
and tricks - T. Modine
13:05-13:50 Recorded LIVE demonstration - A. Assali
c Take-home message - D. Tchetche
41
___12:00-13:00 ______ Room Maillot ____________ 60 minutes inside
Left atrial appendage closure for stroke prevention
What every interventional cardiologist should know
Chairperson: M.W. Bergmann
c To understand the new evidence for left atrial appendage closure
including the PREVAIL trial results
c To define patient selection and access for left atrial appendage closure
while understanding implant mechanics and tissue reaction among
current devices
c To discuss the role of left atrial appendage closure versus
anticoagulation for stroke prevention in atrial fibrillation especially in
patients with comorbidities requiring antithrombotic therapy
c Introduction and objectives - M.W. Bergmann
c Pivotal data for left atrial appendage closure and its meaning for daily
practice: the PROTECT atrial fibrillation and PREVAIL trials - D. Holmes
c Differences among devices: the pathophysiologist’s point of view
R. Virmani
c Preventing stroke in coronary stent patients with atrial fibrillation
C.K. Naber
c Take-home message - M.W. Bergmann
The Portico TAVI system – How new design translates
into clinical results
Chairperson: G. Manoharan
c To understand the consequences of paravalvular leak, pacemaker
implantation and potential clinical sequelae resulting from TAVI
procedures
c To see cases and understand how the design of Portico could mitigate
some of the issues with first generation devices
c To learn about the combined clinical data available on Portico
c Introduction and objectives - F. Maisano
c A critical review of the current challenges in TAVI; pacemaker
implantation and paravalvular leaks - U. Schäfer
c Advancing the practice of medicine through evidence-based
approach: a review of the Portico clinical programme - G. Manoharan
c The Portico TAVI system, designed differently - F. Maisano
c Take-home message - G. Manoharan
__14:10-16:45 _______ Main arena _________________________
Valve-in-valve
Chairpersons: A.P. Kappetein, J. Webb
Panellists: R. Kornowski, T. Walther
c To understand which data should be available prior to a valve-in-valve
procedure
c To appreciate the impact of the availability of valve-in-valve
procedures on surgical valve replacement: who should receive
a bioprosthesis?
c To understand the clinical data and appropriateness
of the valve-in-valve procedure
c Introduction and objectives - J. Webb
c What information is required prior to valve-in-valve procedures?
J. Webb
14:25-14:55 LIVE demonstration from Ferrarotto Hospital - Catania, Italy
c A surgical view: implications of valve-in-valve for surgical valve
replacement and when is valve-in-valve appropriate - T. Walther
c Clinical data from the worldwide registries - R. Kornowski
c Take-home message - A.P. Kappetein
How to prevent and treat ilio-femoral complications of TAVI?
Chairpersons: A. Cremonesi, A. Cribier
c To be familiar with vascular imaging to safely plan transfemoral TAVI
c To know the minimal set of equipment necessary to treat vascular
complications
c To define the role of surgery for gaining access and for treating
peripheral vascular complications
c Introduction and objectives - A. Cribier
c Imaging of vascular anatomy to optimise transfemoral TAVI - F. Civaia
c Case-based discussion - F. Bedogni
c Equipment and strategies for the worst case scenario - C. Mialhe
c Endovascular management of complications - F. Bedogni
c Role of vascular surgery: complication prevention and management
C. Mialhe
c My worst access-related complication - B. Prendergast
c Take-home message - A. Cremonesi
42
___14:55-15:40 _______ Room 353 ______________________Forum
TAVI with coronary artery disease
Under the auspices of the Working Goup on Interventional Cardiology
(EWGIC) of the Egyptian Society of Cardiology and the Working Group on
Interventional Cardiology of the Lebanese Society of Cardiology
Chairpersons: S. El Tobgy, Z. Ghazzal
Sweden shares its most educational cases
the Swedish Society of Cardiology
Chairperson: G. Olivecrona
c To understand the subtle nuances of patients undergoing TAVI
c To learn the approach to patients with severe aortic stenosis and
coronary artery disease undergoing TAVI
c To evaluate the management options in patients undergoing TAVI and
who have other comorbid conditions
c Introduction and objectives - Z. Ghazzal
c Case presentation: TAVI in the presence of significant coronary artery
disease - G. Ghanem
- How would I treat? - M. Sobhy
- How would I treat? - A. Sarkis
- How did I treat? - G. Ghanem
- Consensus - Z. Ghazzal
c Case presentation: TAVI with concomitant coronary artery disease
A. Khashaba
- How would I treat? - A. Sarkis
- How would I treat? - A. El Etriby
- How did I treat? - A. Khashaba
- Consensus - S. El Tobgy
c Take-home message - S. El Tobgy
Challenging prosthetic mitral valve malfunction
(AGIK) of the German Cardiac Society (DGK) and the Working Group on
Invasive Cardiology of the Italian Society of Invasive Cardiology (SICI-GISE)
Chairpersons: A. Elsaesser, G.P. Ussia
c To identify the best treatment of the degenerative mitral prosthesis
valve in high-risk patients
c To reflect on a beneficial spread: TAVI in degenerated biological mitral
prosthesis
c To learn the best technique of mitral valve implantation
c Introduction and objectives - A. Elsaesser
c Case presentation: degenerated biological mitral prothesis - S. Berti
- How would I treat? - M. Kamler
- How would I treat? - G. Sorropago
- How did I treat? - S. Berti
- Consensus - G.P. Ussia
c Case presentation: paraprosthetic leak in a mitral biological prosthesis
P. Boekstegers
- How would I treat? - F. Maisano
- How would I treat? - H. Ince
- How did I treat? - P. Boekstegers
- Consensus - A. Elsaesser
c Take-home message - G.P. Ussia
c Introduction
c Coronary chronic total occlusion nightmare
c Unnecessary balloon aortic valvuloplasty during TAVI?
c A difficult TAVI case
c Consensus
___15:40-16:40 _______ Room 241 ________ Glimpse into the future
Emerging technologies for transcatheter mitral valve therapies
2013 - Part I: transcatheter mitral valve repair devices
Chairpersons: F. Maisano, N. Piazza
c To appreciate the advancement and role of transcatheter mitral valve
repair devices
c To learn about the value of combination therapy including direct and
indirect annuloplasty
c Introduction: background, complexities and unmet needs - F. Maisano
c Chordal implantation – Neochord, Valtech - F. Maisano
c Indirect annuloplasty – MitraSpan - O. Franzen
c Direct annuloplasty – Valtech, Guided-Delivery Systems, Mitralign,
Micardia-Valcare - L. Büllesfeld
c Future of the MitraClip device – Is it here to stay? - O. Franzen
c Combination therapies – Is there a need and possibility? - A. Vahanian
c Take-home message - N. Piazza
___15:40-16:25 _______ Room 353 ______________________Forum
Argentina shares its most educational cases
Under the auspices of the Argentine College of Interventional
Cardioangiologist (CACI)
Chairperson: E. Torresani
c Introduction
c Polytetrafluoroethylene covered stent to treat coronary perforation
c Embolic stroke during TAVI
c Early leak after closure of patent foramen ovale
c Consensus
43
Edwards TAVI: a predictable procedure with sustained
clinical results
With an unrestricted educational grant from EDWARDS LIFESCIENCES
Chairpersons: A. Vahanian, T. Walther
c To obtain better understanding of how valve science provides for
predictable procedures and outcomes
c To obtain better understanding of how TAVI outcomes have
demonstrated longer term patient benefits
c Introduction and objectives - T. Walther
c A predictable TAVI procedure: valve size choice and deployment
E. Garcia
c Predictable procedural outcomes: minimising complications - U. Schäfer
c Predictable treatment benefits: impact on quality of life - B. Prendergast
c Predictable and sustained clinical outcomes - J. Rodes Cabau
c Take-home message - A. Vahanian
Complex cases of mitral regurgitation
How far can you go with MitraClip?
Chairpersons: S. Baldus, S. von Bardeleben
c To share the experience on managing complex cases applying
advanced MitraClip technique
c To understand the implications of shared experience on your current
clinical practice
c Introduction and objectives - S. Baldus
c Case presentation: severe mitral regurgitation post-TAVI implant
M. Settergren
- How would I treat? - M. Senni
- How did I treat? - M. Settergren
- Consensus - S. Baldus
c Case presentation: severe mitral regurgitation post-heart surgery
S. Scandura
- How would I treat? - J. Van Der Heyden
- How did I treat? - S. Scandura
- Consensus - S. Von Bardeleben
c Take-home message - S. Von Bardeleben
c EAPCI Membership
c Stent for Life initiative
c Registries – TAVI, CICD, ACS
c EuroPCR
c PCR London Valves
c EuroIntervention
___17:30-18:15 _______ Room 353 ______________________Forum
Greece shares its most educational cases
the Hellenic Cardiological Society
Chairperson: K. Toutouzas
c Introduction
c A case of unexpected vascular complication after TAVI: fragile arterial
wall of the elderly?
c If unnoticed, a left ventricle perforation can become even more
catastrophic
c Unexpected massive iatrogenic thrombus embolisation
c Consensus
Not to be missed...
44
__09:00-12:30 _______ Main arena _________________________
___09:00-11:00 _______ Room 251 ________ Glimpse into the future
Emerging technologies for transcatheter mitral valve therapies
2013 - Part II: transcatheter replacement technologies
Chairpersons: F. Maisano, N. Piazza
___09:00-10:30 ____ Theatre Bordeaux____________Plenary session
SOLACI@EuroPCR
With the collaboration of the Sociedad Latino Americana de Cardiologia
Intervencionista (SOLACI)
Chairperson: O. Mendiz
Panellists: A. Abizaid, J. Belardi, D. Echeverri, J.A. Mangione, M. Queiroga
c To learn about various approaches to common structural heart
diseases in LATAM
c To exchange opinions between LATAM and the rest of the world
about different interventional approaches to structural heart disease
c Introduction - O. Mendiz
c Why we should close patent foramen ovale
c Mitral valve repair. Where we are what we would expect for LATAM in
the near future - R. Quesada
c TAVI – Case complication presentation - M. Perin
c How to present TAVI complications with current technology - A. Dager
c Value of new devices for improving outcomes - E. Grube
c Take-home message
c To appreciate the advancement and role of transcatheter mitral valve
replacement devices
c To appreciate the advancement and role of transcatheter therapies for
failing surgical mitral bioprostheses
c Introduction: background, complexities and unmet needs - F. Maisano
c CardiaQ - L. Sondergaard
c Neovasc Tiara bioprosthesis - S. Banai
c MitrAssist - P.J. Fitzgerald
c Medtronic mitral valve programme - N. Piazza
c Lutter valve update - G. Lutter
c Valtech - F. Maisano
c Percutaneous repair versus replacement – What should we learn from
the surgical experience? - R. Lange
c The future of transcatheter mitral valve therapies: repair or
replacement? - H. Treede
c Take-home message - N. Piazza
TAVI or not TAVI: that is the question
and the Working Group on Interventional Cardiology of the Spanish Society
of Cardiology
Chairpersons: J. Goicolea, D. Hildick-Smith
c To learn the process by which good decisions are made regarding TAVI
c To understand the workings of a good multidisciplinary team
c To understand the uncertainty surrounding appropriate decisions
regarding TAVI
c Introduction and objectives - D. Hildick-Smith
c Case presentation: treating a nonagenarian with severe aortic stenosis
and severe coronary artery disease - P. Haworth
- How would I treat? - M. Pan
- How did I treat? - P. Haworth
c Case presentation: aortic stenosis and chronic obstructive airways
disease - Is it lungs or the heart, or both? - E. Garcia
- How would I treat? - M. Pan
- How did I treat? - E. Garcia
- Consensus - J. Goicolea
c Take-home message - J. Goicolea
___09:00-09:45 _______ Room 353 ______________________Forum
Israel shares its most educational cases
of the Israeli Heart Society
Chairperson: R. Kornowski
c Introduction
c TAVI with all its possible complications: when hell breaks loose...
c An unrealised nightmare
c Detachment of the nose cone following TAVI
c Consensus
45
Severe aortic stenosis combined with coronary artery disease
in high-risk patient
the Hellenic Cardiological Society and the Working Group on Interventional
Cardiology of the Israeli Heart Society
Chairpersons: H. Danenberg, K. Toutouzas
Closing
Main arena
__12:30-13:30 ___________________________________________
Closing
c To understand the complexity, prognosis and evaluation of patient
with combined aortic stenosis and coronary artery disease
c To be updated on the multiple therapeutic options for this patient
with a combination of aortic stenosis and coronary artery disease
c To understand how to optimise the treatment of high-risk patient with
combined aortic stenosis and coronary artery disease
c Introduction and objectives - K. Toutouzas
c Case presentation: severe aortic stenosis in a patient with left main
artery coronary disease - G. Sianos
- How would I treat? - R. Kornowski
- How would I treat? - P. Anthopoulos
- How did I treat? - G. Sianos
- Consensus - K. Toutouzas
c Case presentation: severe aortic stenosis in a patient with diffuse
coronary disease after bypass surgery - R. Jaffe
- How would I treat? - P. Anthopoulos
- How would I treat? - R. Kornowski
- How did I treat? - R. Jaffe
- Consensus - H. Danenberg
c Take-home message - H. Danenberg
Not to be missed...
46
PART III - Peripheral interventions
PERIPHERAL INTERVENTIONS
Opening sessions
Main arena
__10:00-13:00 ___________________________________________
Opening
__13:00-14:30 ___________________________________________
2013 Great Debate
C.K. Naber
___16:45-18:15 ______ Room Maillot _________ How should I treat?
Titanium-nitride-oxide active coated stents in renal applications
The true indications of renal stenting after ASTRAL and after the
introduction of denervation
Chairpersons: J. Ormiston, A.G. Osiev
c To get a clear understanding of what are the real and true indications
of renal angioplasty with stent
c To understand the real benefit of renal angioplasty plus stenting with
or without denervation
c To discuss the benefits of titanium-nitride-oxide active coating stents
in respect to renal artery angioplasty
__14:30-16:30 ___________________________________________
___14:00-16:30 ______ Room Maillot _____________Plenary session
Revascularisation strategies in patients with lower limb disease
Chairpersons: M. Gargiulo, B. Katzen, A. Schmidt
Panellists: L. Dalla Paola, P. Desgranges, R. Ferraresi, A. Sauguet,
G. Torsello
c To know the clinical evaluation and imaging workup of patients with
lower limb occlusive disease
c To assess strengths and limits of the endovascular and surgical
approaches
c To recognise the multidisciplinary nature of the care
c Introduction and objectives - A. Schmidt
c No stent zones?
- Endovascular strategies for “no-stent zones” – common femoral artery
and popliteal artery:
The interventionalist’s view - A. Sauguet
The surgeon’s view - M. Gargiulo
14:19-15:09 LIVE demonstration from Universitäts - Herzzentrum Freiburg Bad Krozingen, Germany
- Take-home message - A. Schmidt
c Superficial femoral artery
- Hot topics of endovascular treatment of superficial femoral artery
disease - A. Schmidt
- Hot topics of surgical treatment of superficial femoral artery disease
G. Torsello
- Take-home message - B. Katzen
c Critical limb ischaemia
- Treatment strategies in patients with critical limb ischaemia:
Diabetic foot ulcers: the interventional options - R. Ferraresi
The surgical options: primary intention or back-up - P. Desgranges
- State-of-the-art management of diabetic ulcers: beyond
revascularisation - L. Dalla Paola
- Take-home message - M. Gargiulo
c Introduction and objectives - A.G. Osiev
c Case presentation: renal artery angioplasty - P. Commeau
- How would I treat? - P. Vandoni
- How would I treat? - F. Tortoledo
- How did I treat? - P. Commeau
- Consensus - J. Ormiston
c Case presentation: denervation case and stenting - J. Ormiston
- How would I treat? - P. Vandoni
- How would I treat? - F. Tortoledo
- How did I treat? - J. Ormiston
- Consensus - A.G. Osiev
c Take-home message - A.G. Osiev
___16:45-17:45 _____Peripheral room ___________________Forum
Complications and great saves on lower limb
Facilitators: R. Ferraresi, T. Todoran, G. Torsello
48
__08:00-12:00 _______ Main arena _________________________
___08:00-09:55 ______ Room Maillot _____________Plenary session
Carotid live session: the “state-of-the-art“ of stroke prevention
Chairpersons: A. Cremonesi, C. Mialhe, C. Schonholz
Panellists: J.P. Becquemin, E. Diethrich, N. Hopkins, B. Katzen,
K. Mathias, J.C. Parodi, B. Reimers, M. Roffi, C. Setacci, F. Veith
c To compare the current treatment modalities of carotid
revascularisation
c To assess “in live“ advantages and disadvantages of surgical and
endovascular procedure
c To evaluate and discuss the different opinions of “world-class“ experts
08:00-09:55 With simultaneous LIVE demonstrations from Maria Cecilia
Hospital - Cotignola, Italy and from Hôpital Henri Mondor, Créteil - France
c Introduction and objectives - A. Cremonesi
c Carotid endarterectomy versus carotid artery stenting: the big debate
is still open - M. Roffi
c Take-home message - F. Veith
Technical and approach issues in renal artery stenting
the Bulgarian Society of Cardiology, the Working Group on Interventional
Cardiology of the Macedonian Society of Cardiology and the Working Group
on Interventional Cardiology of the Romanian Society of Cardiology
Chairpersons: D. Deleanu, S. Kedev, I. Petrov
c To learn the role of radial approach in renal artery stenting and
compatibility with the available devices
c To appreciate the opportunity of renal artery recanalisation for acute
or chronic renal ischaemia
c To share the technical issues of renal artery stenting in vasculitic renal
disorders and in patients with concomitant peripheral artery disease
c Introduction and objectives - D. Deleanu
c Case presentation: renal function salvage with percutaneous staged
intervention for acute and chronic ischaemia in a Takayasu patient
T. Dumitra
- How would I treat? - S. Antov
- How would I treat? - L. Zarma
- How did I treat? - T. Dumitra
- Consensus - D. Deleanu
c Case presentation: transradial approach for renal artery stenting in
patient with abdominal aortic aneurysm - I. Spiroski
- How would I treat? - V. Velchev
- How would I treat? - S. Antov
- How did I treat? - I. Spiroski
- Consensus - S. Kedev
c Case presentation: transradial approach for bilateral renal artery
stenting in patient with resistant hypertension - H. Dimitrov
- How would I treat? - L. Zarma
- How would I treat? - V. Velchev
- How did I treat? - H. Dimitrov
- Consensus - I. Petrov
c Take-home message - I. Petrov
Access is key for carotid artery stenting in complex aortic arches
Chairpersons: A. Cremonesi, C. Mialhe
Panellists: J.P. Becquemin, R. Kovenbach, S. MacDonald, K. Mathias,
M. Roffi, C. Trani
c To be able to estimate the degree of complexity of the carotid artery
stenting based on aortic arch anatomy
c To be familiar with the interventional strategies required to master
transfemoral carotid artery stenting in complex aortic arches
c To gather knowledge on alternative access strategies such as the
transradial and transcervical accesses
c Introduction and objectives - A. Cremonesi
c Tips and tricks for a successful transfemoral procedure - K. Mathias
c Transradial access: my default strategy - C. Trani
c Avoid the aortic arch altogether by transcervical access - S. Macdonald
c Take-home message - C. Mialhe
___10:30-11:15 _______ Room 353 ______________________Forum
Saudi Arabia shares its most educational cases
Under the auspices of the Saudi Arabia Cardiology Interventional Group
(SACIG) of the Saudia Heart Association
Chairperson: M. Balghith
c Introduction
c Right internal carotid pseudoaneurysm after radiation therapy
c Catheter-induced left main dissection
c Myocardial bridging, stent or no stent
c Consensus
Embolic protection devices for carotid artery stenting
Chairpersons: B. Reimers, C. Setacci
Panellists: B. Katzen, R. Kovenbach, J.C. Parodi, A. Sauguet, C. Schonholz,
H. Sievert
c To assess advantages and disadvantages of filter and proximal embolic
protection devices
c To decide the appropriate embolic protection device for the individual
patient
c To gather information on the Michi system
c Introduction and objectives - B. Reimers
c Filters: still the way to go for most patients - B. Katzen
c Proximal protection: necessary in high-risk patients, and valuable in
any patient - J.C. Parodi
c Michi system: the future - R. Kovenbach
c Flow stagnation / flow reversal: main differences and advantages of
each technique - H. Sievert
c Take-home message - C. Setacci
49
___11:15-12:00 _______ Room 353 ______________________Forum
South Africa shares its most educational cases
Under the auspices of the South African Society of Cardiovascular
Visceral and renal artery interventions
Chairpersons: G. Oderich, C. Rabbia
Panellists: J.P. Becquemin, J. Robison, A. Schmidt, C. Setacci,
T. Todoran, J. Van den Berg
c Introduction
c Spontaneous carotid dissection
c Unusual treatment of coronary perforation
c Neurocardiac complication
c Consensus
___12:00-13:30 ______ Room Maillot ________________ Symposium
Access is critical
With an unrestricted educational grant from COOK MEDICAL
Chairpersons: H. Sievert, T. Zeller
c To learn how to choose the best access according to the requirements
of each individual case
c To lower your access complication rate
c To move as many procedures as possible to a percutaneous approach
c Introduction and objectives - T. Zeller
c Carotid access - E.M. Marone
c Radial access - R.H. Stables
c Access to aortic abdominal aneurysm - J. Constantinou
c Pedal access - A. Schmidt
c Take-home message - H. Sievert
__14:10-16:45 _______ Main arena __________________________
c To learn which is the best imaging technology for diagnosis of visceral
and renal artery disease
c To discuss clinical indications for treatment
c Introduction and objectives - C. Rabbia
14:15-14:39 LIVE demonstration from Maria Cecilia Hospital - Cotignola, Italy
c Celiac trunk and superior mesenteric artery stenting
- Anatomy and indications for treatment - J. Robison
- How do I do it? - J. Van Den Berg
- How do I do it? - A. Schmidt
- How do I do it? - G. Oderich
- Open surgical treatment for patients with visceral ischaemia - J. Robison
c Renal artery stenting
- Which are the 2013 indications for renal artery stenting?
- Is there any value for protection during renal artery stenting?
T. Todoran
- The role for surgical revascularisation for renal artery stenosis
J. Robison
c Take-home message - G. Oderich
Guest lectures: how I survived the peripheral endovascular battle?
Chairperson: R. Greenhalgh
Panellists: E. Diethrich, B. Katzen, Z. Krajcer, C. Mialhe, F. Veith
c To hear the peripheral endovascular story from the pioneering time
c To learn how innovation went to daily practice and scientific evidence
c To understand how interdisciplinary conflicts led to multidisciplinary
practice
c Introduction and objectives - C. Mialhe
c As a surgeon - F. Veith
c As an interventional radiologist - B. Katzen
c As an interventional cardiologist - Z. Krajcer
c As evidence-based medicine defender - R. Greenhalgh
50
c Take-home message - E. Diethrich
Facilitators: A. Cremonesi, N. Hopkins, S. MacDonald
___16:45-18:15 ______ Room Maillot ________________ Symposium
___16:45-17:30 _______ Room 353 ______________________Forum
The evolving evidence of IN.PACT drug-eluting balloon
in claudication and critical limb ischaemia
Chairpersons: E. Minar, A. Schmidt
Iran shares its most educational cases
Under the auspices of the Iranian Society of Interventional Cardiology (ISOIC)
Chairperson: M. Hashemian
c To reinforce the role of evidence in clinical decision-making within
the complex peripheral space and recognise the breadth and value of
IN.PACT drug-eluting balloon clinical program
c To understand drug-eluting balloon therapy rationale and clinical
effectiveness built upon patient centered outcomes for both
claudicants and critical limb ischeamia subjects
c To appreciate cost-effectiveness models and metrics for drug-eluting
balloon therapy in claudication and critical limb ischeamia
c Introduction and objectives - E. Minar
c The value of evidence: the IN.PACT drug-eluting balloon case example
K. Rocha-Singh
c IN.PACT in superficial femoral artery for claudicants - A. Micari
c IN.PACT in below the knee for critical limb ischaemia - A. Schmidt
c Cost effectiveness of leaving nothing behind - T. Zeller
c Take-home message - A. Schmidt
c Introduction
c Bilateral critical carotid stenosis complicated by long dissection,
requiring multiple stents implantation
c Post-operative perforation of pseudo-aneurysm of coarctation of aorta
requiring emergency stenting of the lesion complicated with type 2
endoleak
c Neglected external iliac artery perforation, during coronary PCI
c Consensus
___16:45-17:45 _____Peripheral room ___________________Forum
Complications and great saves on carotid interventions
51
__08:00-12:00 _______ Main arena _________________________
Solutions for complex abdominal aortic aneurysm
Chairpersons: J.P. Becquemin, K. Ivancev, Z. Krajcer
Panellists: M. Davis, S. Haulon, B. Katzen, G. Oderich, J.C. Parodi,
C. Schonholz, G. Torsello, J. Van den Berg
c To identify indications for endovascular procedures
c To learn how to preserve main side branches
c To learn how to prevent complications
c Introduction and objectives - J.P. Becquemin
08:05-08:40 LIVE demonstration from Hôpital Henri Mondor - Créteil, France
c Back to the future of EVAR - J.C. Parodi
c Branched revascularisation techniques:
- Branched and fenestrated endografts - S. Haulon
- Chimney technique - G. Torsello
- Sandwich technique - C. Schonholz
c How to tailor our procedures and improve outcomes:
- How to choose an endograft? - G. Torsello
- Which type II endoleaks needs to be treated? - B. Katzen
- When and how to exclude internal iliac? - J. Van Den Berg
- When and how to preserve internal iliac? - G. Oderich
- How to prevent complications in complex procedures? - M. Davis
How I treat complications after peripheral endovascular
intervention
Under the auspices of the Italian Society for Vascular and Endovascular
Surgery (SICVE) and the Vascular Surgery Society of Southern Africa (VASSA)
Chairpersons: J. Pillai, C. Setacci
c To learn how to treat real life complex cases
c To understand the differences in everyday practice in different
countries
c To discuss how to surgical manage endovascular complications
c Introduction and objectives - C. Setacci
c Case presentation: carotid pseudoaneurysm after carotid artery
stenting - P. Sirignano
- How would I treat? - J. Tunnicliffe
- How would I treat? - G. Marcucci
- How did I treat? - P. Sirignano
- Consensus - C. Setacci
c Case presentation: ruptured iliac artery following balloon angioplasty
T. Mulaudzi
- How would I treat? - G. Marcucci
- How would I treat? - J. Tunnicliffe
- How did I treat? - T. Mulaudzi
- Consensus - J. Pillai
c Take-home message - J. Pillai
You are a practitioner who wishes to start or is starting
a peripheral percutaneous transluminal angioplasty programme:
how to succeed?
Facilitators: A. Sauguet, E. Stabile
Panellists: G. Ducrocq, C. Mialhe
c To better understand how to select appropriate material
Therapeutic embolisation - Part I: tools and techniques
Chairpersons: C. Rabbia, C. Schonholz
Panellists: A. Belli, J. Lammer, J. Van den Berg
c Introduction and objectives - C. Schonholz
10:05-10:55 LIVE demonstration from Hôpital Européen Georges
Pompidou - Paris, France
c Introduction and classification of embolic agents
- Mechanical embolic agents:
Free delivery and detachable coils - J. Lammer
Vascular occluders - C. Schonholz
- Particulate embolic agents:
Gelfoam – Polyvinyl alcohol particles - J. Van Den Berg
Microspheres and other new embolic agents - J. Van Den Berg
- Liquid embolic agents:
Cyanoacrylate – Onyx - A. Belli
c Take-home message - C. Rabbia
___13:05-14:05 ______ Room Maillot ___________ 60 minutes inside
New hopes for critical limb ischaemia
Chairpersons: V. Prochazka, B. Reimers
c To understand newest trends in treatment of critical limb ischaemia
c To appreciate benefits of cell therapy in no option critical limb
ischaemia
c Introduction - B. Reimers
c RX technology for optimised treatment of critical limb ischaemia
J. Ruef
c Go subintimal below the knee! - R. Ferraresi
c Cell therapy: promising option for no option critical limb ischaemia
patients? - J. Madaric
c Take-home message - V. Prochazka
52
Emerging clinical use of drug-eluting balloon in challenging
atherosclerotic lesions
Chairperson: G. Richardt
How to prevent and treat ilio-femoral complications of TAVI?
Chairpersons: A. Cremonesi, A. Cribier
c To understand the specific characteristics of the Lux technology and
its potential benefits
c To assess clinical results of the Lux technology in coronary or
peripheral lesions
c Introduction and objectives - G. Richardt
c How I translate the Pantera Lux results into my daily practice - R. Tölg
c BIOLUX-I case examples: using drug-eluting balloon to optimise
bifurcation treatments - P. Antonis
c Management of femoro-popliteal indications: illustrative examples
from the BIOLUX P-I trial - A. Schmidt
c Take-home message - G. Richardt
__14:10-16:45 _______ Main arena _________________________
Solutions for complex thoracic aortic disease
Chairpersons: S. Haulon, J. Lammer, C. Nienaber
Panellists: N.J. Cheshire, G. Dreyfus, K. Ivancev, J.C. Parodi, V. Riambau,
H. Rousseau, C. Schonholz
c To identify today’s indications for endovascular procedures
c To learn how to preserve main side branches
c Introduction and objectives - C. Nienaber
14:13-14:42 LIVE demonstration from Hôpital Henri Mondor - Créteil, France
c Branched revascularisation techniques:
- Branched endografts - S. Haulon
- Endovascular option for ascending aorta - V. Riambau
c Off the shelf branched grafts:
- Gore Medical - C. Schonholz
- Bolton Medical - H. Rousseau
- Cook Medical - K. Ivancev
c How to tailor our procedures and improve outcomes:
- When is it necessary to place an endograft for type B uncomplicated
dissection? - C. Nienaber
- Which entry tears need to be covered in thoracic dissection?
J.C. Parodi
- How to deal with thoracic dissection extended to visceral arteries?
N.J. Cheshire
- How to deal surgically with retrograde thoracic dissection after
endografting of the descending thoracic aorta? - G. Dreyfus
c Take-home message - S. Haulon
c To be familiar with vascular imaging to safely plan transfemoral TAVI
c To know the minimal set of equipment necessary to treat vascular
complications
c To define the role of surgery for gaining access and for treating
peripheral vascular complications
c Introduction and objectives - A. Cribier
c Imaging of vascular anatomy to optimise transfemoral TAVI - F. Civaia
c Case-based discussion - F. Bedogni
c Equipment and strategies for the worst case scenario - C. Mialhe
c Endovascular management of complications - F. Bedogni
c Role of vascular surgery: complication prevention and management
C. Mialhe
c My worst access-related complication - B. Prendergast
c Take-home message - A. Cremonesi
Therapeutic embolisation - Part II: clinical applications
Chairpersons: Z. Krajcer, J. Lammer
Panellists: F. Bourlon, B. Katzen, H. Rousseau
c Introduction and objectives - J. Lammer
15:45-16:03 LIVE demonstration from Hôpital Européen Georges Pompidou Paris, France
c Clinical applications:
- Inferior mesenteric artery and lumbar arteries embolisation prior to
aortic abdominal aneurysm repair - J. Lammer
- Embolisation for endoleaks - H. Rousseau
- Visceral artery aneurysms - B. Katzen
- Embolisation for coronary artery fistulas - F. Bourlon
___16:45-18:15 ____ Peripheral room ____________Plenary session
Complication forum: ISES@EuroPCR
With the collaboration of the International Society of Endovascular
Specialists
Facilitators: E. Diethrich, Z. Krajcer, C. Schonholz
c To review cases with complications
c To discuss how to avoid complications
c To learn how to manage complications
53
c EAPCI Membership
c EuroPCR
c PCR London Valves
c EuroIntervention
54
__09:00-12:30 _______ Main arena _________________________
All you need to know about drug-coated balloons
in coronary and peripheral vascular disease
Chairpersons: B. Scheller, P. Meier
Hybrid angio suite
Chairpersons: I. Kobeiter, C. Mialhe
Panellists: N.J. Cheshire, C. Schonholz , H. Sievert
c To identify practice requirements for each specialty
c To draw the 3-dimensional ideal layout for each specialty
c To foresee what will be tomorrow suite for next generation
practitioner
c Specialty requirements:
- Requirement for interventional cardiology and correlated 3D layout
H. Sievert
- Requirement for interventional radiology and correlated 3D layout
I. Kobeiter
- Requirement for endovascular surgery and correlated 3D layout
C. Mialhe
- Should we consider robotic surgery when planning a new hybrid
room? - N.J. Cheshire
c Company proposal:
- Siemens 3D scheme best compromise
- Philips 3D scheme best compromise
- GE 3D scheme best compromise
- Toshiba 3D scheme best compromise
c Take-home message - C. Schonholz
clinical practice
future
c Introduction - B. Scheller
c Background: local drug delivery - P. Meier
c Clinical data: results in coronary and peripheral arteries - B. Cortese
c Issues in clinical practice - B. Scheller
c Guidelines and recommendations: current clinical applications
C.K. Naber
J. Granada
c Conclusion - P. Meier
Closing
Main arena
__12:30-13:30 ___________________________________________
Closing
Large size percutaneous access for endoaortic procedures
Chairpersons: S. Berti, C. Mialhe
Panellists: E. Allaire, P. Desgranges, I. Kobeiter, Z. Krajcer, H. Sievert,
D. Tchetche, G. Torsello
c To learn the percutaneous access technique
c To learn how to treat complications
10:50-11:20 Recorded cases
c Percutaneous access and arterial closure:
- Anatomical issues - E. Allaire
- Arterial closure devices - Z. Krajcer
- Step-by-step procedure - Z. Krajcer
- Introducer sheaths selection - G. Torsello
c Indications:
- Access for aortic endograft - C. Mialhe
- Access for TAVI - D. Tchetche
- Endovascular management of complications - I. Kobeiter
- Surgical treatment of complications - P. Desgranges
c Take-home message - S. Berti
55
TRAINING VILLAGE
Room Cordis
___09:00-10:00 ____________________________________________
Endovascular complication management: renal access
Trainer: A. Cremonesi
c To review and discuss possible complications during renal procedures
c To introduce techniques and material to handle renal complications
c To review renal cases
56
PART IV - Interventions for hypertension
and heart failure
INTERVENTIONS FOR HYPERTENSION AND HEART FAILURE
Opening sessions
Main arena
__10:00-13:00 ___________________________________________
Opening
__13:00-14:30 ___________________________________________
2013 Great Debate
C.K. Naber
__14:30-16:30 ___________________________________________
Selecting the right patient for catheter-based renal sympathetic
denervation: a case-based discussion
Chairperson: F. Mahfoud
c To understand the process of appropriate patient screening
c To appreciate how to identify the best candidate for catheter-based
renal sympathetic denervation
c To understand potential causes for lack of responsiveness to the
denervation procedure
c Introduction and objectives - F. Mahfoud
c Case presentation: patient with resistant hypertension and
hypertensive end organ damage – An ideal candidate - C. Ukena
c What does the literature tell us – An update on recent clinical data
R. Schmieder
c Case presentation: patient with pseudo-resistant hypertension
A. Kaltoft
c What does the literature tell us – How to assess and handle
pseudo-resistant hypertension
c Case presentation: patient with chronic kidney disease and
hypertension - E. Wyffels
c What does the literature tell us – What to do in patients with impaired
renal function - F. Mahfoud
c Case presentation: patient with no blood pressure response following
renal denervation - E. Blessing
c What does the literature tell us – What to do with non-responders
M. Böhm
c Case presentation: patient with secondary hypertension
c What does the literature tell us – Pitfalls in screening for secondary
causes of hypertension - M. Lobo
c Take-home message
Catheter-based renal sympathetic denervation: long-term
SYMPLICITY clinical evidence, new data and future perspectives
Chairperson: F. Mahfoud
Panellists: J. Davies, D. Kandzari, R. Schmieder, J. Weil
c To understand the latest long-term clinical evidence from SYMPLICITY
HTN-1 (3-year), SYMPLICITY HTN-2 (2-year) and real-world global
SYMPLICITY registry
c To understand the clinical data on the effects of catheter-based renal
sympathetic denervation in other disease processes where increased
sympathetic tone plays a role in disease pathogenesis
c To understand the importance of, and the approach to, building new
catheter-based renal sympathetic denervation referral networks
c Update on SYMPLICITY clinical trials - D. Kandzari
c Update on global SYMPLICITY registry - F. Mahfoud
Where to from here for catheter-based renal sympathetic denervation
clinical studies?
c Extending to stage 1 refractory hypertension - R. Schmieder
c Expanding to heart failure - J. Davies
c Building a successful renal denervation referral networks – Panel
discussion and audience interaction - J. Weil
c Take-home message - F. Mahfoud
Not to be missed...
…the Training programme
c Catheter-based renal sympathetic denervation: introduction to an
irrigated technology
With an unrestricted educational grant from MEDTRONIC ACADEMIA
c Hands-on introduction to the new Symplicity Spyral renal
denervation system
c Catheter-based renal sympathetic denervation
58
__08:00-12:00 _______ Main arena _________________________
__14:10-16:45 _______ Main arena __________________________
Advancing innovations on catheter-based renal sympathetic
denervation: when safety meets efficacy
An interactive clinical-based symposium
CORDIS, JOHNSON & JOHNSON
Chairpersons: M. Böhm, V. Reddy
c To discuss technical limitations with current renal sympathetic
denervation devices and their significance on clinical results
c To learn about new renal sympathetic denervation options and
understand how these might address current clinical outcomes
c To analyse histopathological data of irrigated versus non-irrigated
ablation and their implications on safety and efficacy
c Introduction and objectives - M. Böhm
c Treatment of resistant hypertension by renal sympathetic denervation.
Epidemiological analysis and current limitations. Future of renal
sympathetic denervation - P.J. Blankestijn
c The helical multiplex-electrode irrigated catheter approach
M. Sapoval
c Clinical case based presentation. Human data illustration - A. Kaltoft
c Expected clinical benefits and safety implications of catheter-based
irrigated ablation - V. Reddy
c Hystopatological assessment of sympathetic renal denervation with
irrigated catheter - R. Virmani
c Presentation of recent clinical investigation results - W. Wijns
c Take-home message - V. Reddy
Resistant hypertension and its treatment across the world
Chairpersons: R. Gao, A. Pathak
c To understand potential regional differences in diagnosis of resistant
hypertension and treatment options
c To learn about technical challenges of renal denervation and potential
solutions
c Introduction and objectives - R. Gao
c Case presentation - X. Jiang
c Treatment of resistant hypertension: from basic science to clinical
practice - A. Pathak
c Resistant hypertension – Do we have the same understanding?
- View from Asia - R. Gao
- View from Europe - H. Benamer
- View from Brazil - B.O. Almeida
c Anatomic challenges of renal artery and radial access - H. Benamer
c Take-home message - R. Gao
Device-based interventions in heart failure: targeting deleterious
mechanisms of heart failure progression
Chairpersons: J. Bartunek, D. Burkhoff
c To understand the role of device-based therapies in the current
multidisciplinary management of heart failure
c To become familiar with the therapeutic potential of devices
interfering with neurohumoral pathways and addressing the structural
remodeling in heart failure
c To understand the role of assist devices in management of acute and
chronic heart failure
c Introduction and objectives - J. Bartunek
c Catheter-based renal sympathetic denervation in systolic and diastolic
heart failure - M. Böhm
c Electrical vagal stimulation for heart failure - F. Mahfoud
c Interventions targeting left ventricular remodeling - D. Burkhoff
c Assist devices in acute and chronic heart failure
c Take-home message - D. Burkhoff
___16:45-18:45 ____ Theatre Bordeaux _____ Tools & Techniques (TNT)
The next frontier for catheter-based renal sympathetic
denervation for patients with resistant hypertension
With an unrestricted educational grant from COVIDIEN
Chairpersons: D. Scheinert, N. Werner
c To consider the endpoints and evidence required for successful
catheter-based renal sympathetic denervation for patients with
resistant hypertension
c To understand the procedural, safety, and efficacy potential for
next generation catheter-based renal sympathetic denervation
technologies
c To understand the performance and potential of irrigated radiofrequency catheter-based renal sympathetic denervation technology
c Introduction and objectives - N. Werner
Germany
c How do we measure success of catheter-based renal sympathetic
denervation therapies - R. Schwartz
c What do second generation catheter-based renal sympathetic
denervation devices bring to the table? - A. Belli
Germany
c OneShot catheter-based renal sympathetic denervation clinical data:
what we have learned - S. Verheye
c Take-home message - D. Scheinert
59
… Wednesday 22nd May, 2013
Catheter-based renal sympathetic denervation
Building momentum with the next generation Vessix system
Chairpersons: T. Lüscher, F. Mahfoud
c To learn how the pre-clinical and clinical evidence for catheter-based
renal sympathetic denervation, to treat resistant hypertension, is
being built
c To demonstrate the Vessix multi-point system features and its
anatomical and clinical use
c To understand the importance of establishing appropriate patient
pathways and selection criteria as it pertains to management of
refractory hypertension
c Pre-clinical insights in catheter-based renal sympathetic
denervation – laying the foundations - M. Mazor
c Clinical evidence in catheter-based renal sympathetic
denervation – building the data - J. Schofer
c The next generation Vessix device – all you need to know - E. Wyffels
c Patient pathways in hypertension – implications for your practice
G. Grassi
Not to be missed...
denervation system
60
___09:45-11:45 _____ Theatre Havane _________________________
__08:00-12:00 _______ Main arena _________________________
Revascularisation in a patient with ischaemic heart failure
and reduced left ventricular function
Chairpersons: P. Kolh, T. Lüscher
Panellists: J. Bartunek, P. Kala
c To apply appropriate revascularisation strategies in patients with
ischaemic heart failure
c To understand open issues surrounding revascularisation treatment
for heart failure patient and the need for a patient-tailored and heart
team-guided multidisciplinary approach
c To understand the role of catheter-based devices for haemodynamic
support during high-risk PCI
c Introduction and objectives - P. Kolh
c Revascularisation strategies in patients presenting with heart failure:
clinical assessment and contemporary guidelines - J. Bartunek
Germany
c Revascularisation strategies in congestive heart failure patients: a
synthesis of current knowledge and open questions - P. Kala
___08:00-09:30 ______ Room 252AB ___All you need to know about...
All you need to know about catheter-based renal
sympathetic denervation
Chairpersons: F. Mahfoud, R. Whitbourn
clinical practice
future
c Introduction - F. Mahfoud
c Background - R. Schmieder
c Clinical data - R. Whitbourn
c Issues in clinical practice - T. Zeller
c Guidelines and recommendations - A. Witkowski
c Unresolved issues and outlook - F. Mahfoud
c Conclusion - R. Whitbourn
Learning renal denervation
Critical appraisal of CE-marked device-based therapies
targeting the sympathetic system
Facilitators: F. Mahfoud, C. Ukena, T. Zeller
c To get a critical overview of key information on the current CE-marked
catheter-based renal sympathetic denervation and baro-reflex
activation therapies
c To understand which are the interventional features of the different
technologies and tips and hints to achieve an optimal outcome with
each device
c To better understand what key information should be collected and
monitored for valid long-term evaluation
Clinical update on EnligHTN, the original multi-electrode
catheter-based renal sympathetic denervation system
Chairpersons: M. Böhm, T. Lüscher
c To be updated on EnligHTN clinical programme and effectiveness in
real-world practice
c To understand from the current evidence which patients best benefit
from catheter-based renal sympathetic denervation
c To appreciate the current level of evidence available on EnligHTN and
the pipeline of future clinical studies
c Introduction and objectives - T. Lüscher
c Developing consensus: which of your patients benefit from
catheter-based renal sympathetic denervation? - M. Böhm
c EnligHTN second generation catheter-based renal sympathetic
denervation system – setting the new benchmark - S. Worthley
c Advancing the practice of medicine through evidence-based
approach: a review of the EnligHTN clinical programme - M. Lobo
c The EnligHTN real-world experience with focus on patient flow
J. Boergel
__14:10-16:45 _______ Main arena _________________________
61
Effect of catheter-based sympathetic denervation
is there a role beyond resistant hypertension?
Chairpersons: M. Böhm, R. Cifkova
c To appreciate the potential of catheter-based renal sympathetic
denervation for new indications, such as sleep disorders, metabolic
syndrome, heart failure or arrhytmias
c Introduction and objectives - R. Cifkova
c Why has renal denervation multiple effects beyond hypertension?
M. Böhm
c Metabolic syndrome and diabetes - A. Pathak
c Sleep apnea syndrome - A. Witkowski
c Heart rate and cardiac arrhythmias - C. Ukena
c Chronic kidney disease and renal function - R. Schmieder
c Take-home message - M. Böhm
c EAPCI Membership
c EuroPCR
c PCR London Valves
c EuroIntervention
Introducing the new Symplicity Spyral and Flex systems
Chairpersons: M. Böhm, T. Zeller
Panellists: E. Blessing, H. Sievert
Attend this session if you want :
c To make the best evidence-based decisions based on the latest
SYMPLICITY clinical data
c To understand how the new Symplicity technology systems provide
optimal treatment for both straightforward and complex cases
c To learn case tips and tricks and see how the new multi-electrode
Symplicity Spyral drives greater procedural efficiency while Symplicity
Flex provides procedural versability
c Introduction and objectives - M. Böhm
c New SYMPLICITY clinical data: what does it tell us? - T. Zeller
c SYMPLICITY in the real world: what have we learned? - M. Böhm
17:45-18:25 Recorded LIVE demonstration - H. Sievert
c New Symplicity technology: what is it and how to use it?
R. Whitbourn
c The new Symplicity technology portfolio: what to use, when?
E. Blessing
c Take-home message - T. Zeller
Not to be missed...
denervation system
62
__09:00-12:30 _______ Main arena _________________________
Closing
Closing
Main arena
__12:30-13:30 ___________________________________________
Device-based left ventricular cavity reduction in heart failure
Chairpersons: M. Costa, C. Ruiz
Panellists: J. Bartunek, H. Ince
c To become familiar with percutaneous interventions aimed at left
ventricular cavity reduction in heart failure
c To understand the potential role of ventricular remodeling and
reconstructive interventions in heart failure management
c To become familiar with procedural aspects of percutaneous
techniques of ventricular partitioning
c Introduction and objectives - C. Ruiz
c Device-based treatment in heart failure: defining the treatment goals
and emerging therapeutic solutions - H. Ince
11:05-11:50 LIVE demonstration from St Thomas’ Hospital - London,
United Kingdom
c Catheter-based left ventricular reconstruction in chronic heart failure:
is it ready for “prime time”? - J. Bartunek
c Take-home message - M. Costa
Tips and tricks for a successful catheter-based renal sympathetic
denervation in difficult anatomies
Chairpersons: T. Lüscher, F. Mahfoud
Panellists: E. Blessing, F. Mahfoud, M. Sapoval, R. Whitbourn, T. Zeller
c To understand renal artery anatomy as relevant for intervention
c To master tips and tricks to treat challenging anatomies
c To understand how to handle complications during catheter-based
renal sympathetic denervation
c Overview: renal artery anatomy for interventionalists - M. Sapoval
c Case presentation: what to use in tortuous arteries - E. Blessing
c Case presentation: how to get access to renal arteries with deep
angles? - A. Cremonesi
c Case presentation: what to do in patients with polar arteries and short
stem? - F. Mahfoud
c Case presentation: what to do in patients with renal artery stenosis or
fibromuscular dysplasia? - T. Zeller
c Case presentation: how to handle potential complications
R. Whitbourn
Not to be missed...
denervation system
63
PART V - Nurses and technicians
NURSES AND TECHNICIANS
Opening sessions
Main arena
__10:00-13:00 ___________________________________________
Opening
__13:00-14:30 ___________________________________________
2013 Great Debate
C.K. Naber
__14:30-16:30 ___________________________________________
___15:30-16:30 _______ Room 251 ___________________________
TAVI update
Chairpersons: M. Oberhoff, V. Rodriguez Garcia-Abad
c To review the patient assessment for TAVI and the role of the TAVI
nurse
c To understand the impact of aortic regurgitation post-TAVI
c To be updated on the characteristics of new valves and their
performance
c Introduction and objectives - V. Rodriguez Garcia-Abad
c New indications on TAVI - M. Van Der Heijden
c Optimising the care of the TAVI patient by developing a TAVI nurse
specialist - B.H. Kirk
c Predictors of complications in patients undergoing percutaneous
aortic valve implantation - J. Maristany
c Technical aspects of the new valves: access and implantation - T. Vonck
c Take-home message - M. Oberhoff
___14:00-15:30 _______ Room 251 ___________________________
Current and future technologies in the cathlab
Chairpersons: M. Oberhoff, M. Van Der Heijden
c To be updated about the latest developments in interventional
medicine
c To compare different intracoronary imaging techniques for the
assessment of coronary lesions
c Welcome - M. Oberhoff
c Introduction and objectives - M. Oberhoff
c New imaging modalities for lesion assessment (OCT and near-infrared
spectroscopy) - B. Loejmand
c Bioresorbable scaffolds - V. Rodriguez Garcia-Abad
c Self-expandable stents in STEMI - R. Deible
c Dedicated bifurcation stents - M. Oberhoff
c Catheter-based renal sympathetic denervation - L. Hinterbuchner
c Take-home message - M. Van Der Heijden
65
___08:00-09:30 _______ Room 251 ___________________________
___15:40-16:40 _______ Room 251 ___________________________
Primary PCI in complex STEMI with cardiogenic shock
Chairpersons: R. Vermeulen, M. Wizimirski
Pre-procedure risk assessment to prevent complications
after/ during PCI
Chairpersons: A. Lugtigheid, R. Vermeulen
STRELNIFTE
FO
c To appreciate the specific needs and preparation in the catheterisation
laboratory for the management of shock patients
c To debate priorities when performing PCI in these patients
c To understand how to apply cooling and support devices to improve
patient outcome
c Introduction and objectives - R. Vermeulen
c Things we need to have ready in the cathlab for this patient
M. Wizimirski
c How to consent a STEMI patient? - P. Behrndtz
c What to do next? Priorities from start to finish - M. Hawkey
c Therapeutic cooling after cardiac arrest - R. Deible
c Mechanical circulatory support devices in cardiogenic shock
A. Lugtigheid
c Take-home message - M. Wizimirski
___09:45-11:15 _______ Room 251 ___________________________
c To understand and be able to apply the available risk scores for patient
assessment before PCI
c To understand how to monitor patients status during PCI
c To master the different preventive measures that can avoid contrastinduced nephropathy, bleeding and other complications
c Introduction and objectives - A. Lugtigheid
c The use of checklists to prevent complications - D. Zughaft
c Reducing bleeding complications: vascular approach and assessment
of antithrombotic medications - V. Oriolo
c How to prevent contrast induced nephropathy - R. Esteves
c Vital signs during PCI: what to observe and when to act - M. Jacobs
c Take-home message - R. Vermeulen
Learning FFR
Assisting for FFR measurement in the cathlab (N&T)
Facilitators: S. Buendia, M. Oberhoff
c To review the basic principles of FFR measurement
c To better understand the step-by-step procedure
c To identify the potential pitfalls during FFR procedure
___12:00-13:00 __ Nurses and Technicians Corner _______________
Moderated poster presentations
Facilitator: M. Leahy
___14:10-15:40 _______ Room 251 ___________________________
Assisting for PCI through radial approach
Chairpersons: S. Buendia, V. Rodriguez Garcia-Abad
c To become fully familiar with the radial approach for PCI, including its
application during primary PCI for STEMI
c Introduction and objectives - S. Buendia
c How to select the patient. Indications, contraindications, advantages
and disadvantages - D. Kerrigan
c How to assist in radial PCI including primary PCI
V. Rodriguez Garcia-Abad
c Specific materials to perform radial PCI - E. Calvo Barriuso
c Haemostasis following radial vascular access - V. Kwok
c Current research data on radial approach - L. Hinterbuchner
c Take-home message - S. Buendia
66
___08:00-09:30 _______ Room 251 ___________________________
Best clinical abstract presentations
Chairpersons: L. Kløvgaard, D. Zughaft
c To listen to the best clinical abstracts submitted this year
c To listen to and discuss interesting topics we meet on daily basis in the
cathlab
c Introduction and objectives - L. Kløvgaard
c The role of the study nurse during clinical stent trials - L. Morsiani
c Promoting excellence and quality through a multidisciplinary forum
L. Boyd
c Influence of manual versus automated pump contrast injection on
imaging quality of optical coherence tomography - B. Lenaerts
c Radiation doses in interventional cardiology procedures in
comparison with reference level: one year single centre experience
A. Maschera
c The implication of clinical governance in cathlab - M. Ghorbati
c Take-home message - D. Zughaft
_11:15-11:45 _______ Room 251 _________________________
Nurses and Technicians best presentation award and closing
ceremony
Chairpersons: S. Buendia, L. Kløvgaard, M. Oberhoff, R. Vermeulen
c Best 2013 Nurses and Technicians presentation
c Presentation by the awardee
c Closing remarks
___09:45-11:15 _______ Room 251 ___________________________
Best nurse research abstract session
Chairpersons: M. Hawkey, L. Kløvgaard
c To interpret and discuss results from nurse-driven clinical trials
c To understand the impact of research on patient care
c Introduction and objectives - L. Kløvgaard
c How to develop and maintain a research culture in a busy cathlab
H. Phillips
c Re-presentation, symptom attribution and psychological health
following primary PCI: a prospective cohort study - H. Phillips
c The analgesic effect of oxygen during PCI (The OXYPAIN trial)
D. Zughaft
c Contrast medium induced nephropathy in patients undergoing PCI
for ACS - R. Esteves
c Immediate mobilisation after PCI following haemostasis with the
AngioSeal vascular closure device - E. Larsen
c Take-home message - M. Hawkey
Closing
Main arena
__12:30-13:30 ___________________________________________
Closing
67
TRAINING VILLAGE
Room Cordis
Room Cordis
___17:30-18:30 ____________________________________________
___09:00-10:00 ____________________________________________
Femoral artery access and hemostasis
Trainer: L. Lonn
Trainer: E. Wyffels
c To get an overview of femoral artery anatomy and proper techniques
in obtaining common femoral artery access
c To learn about sheath removal and haemostasis techniques
c To review complications and management of femoral artery access
c To be introduced to Cordis catheter-based renal sympathetic
denervation technology
c To review and discuss the advantages of irrigation
c To get hands-on with the device
Room Cordis
___16:45-18:00 ____________________________________________
Importance of vessel pre- and post- dilatation for better patient
outcomes
Trainer: H. Rittger
c To learn about the importance of lesion preparation and post-stent
dilatation for procedure outcome
c To review and discuss different interventional techniques and
materials
68

Scientific programme update

Transcription

Documents pareils

Riser card PCI Express x8 angled 90° left insertion

PCIe - Extension Riser Card x8 > x16

DGE-528T PCI Gigabit Ethernet Adapter

DOD 003265

PX-313

Cardiovascular Risk Reduction at UnitedHealthcare of North Carolina

Annual Report Division of Cardiology, Department of Medicine Sir

PCIe-8560/PXI-8565

FWBX2-PCIE1XE220 Dual Channel 4-port OHCI

Bleeding versus stent thrombosis: can short DAPT be safe in